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Abstract 
A new diffusely infiltrating glioma mouse model reveals neuronal alterations in the brain tumor 
microenvironment 
Daniela Torres 
Gliomas are brain tumors that present with neurological symptoms including seizures and 
cognitive deficits. Starting at early stages of tumor development glioma cells diffusely infiltrate 
brain tissue where they interact with non-neoplastic cells including neurons and can perturb 
normal brain function. While the clinical consequences of glioma induced cortical dysfunction 
are well established, the neuronal alterations that underlie cortical dysfunction in glioma are 
unknown. We hypothesize that glioma cells infiltrate surrounding brain tissue and induce 
alterations in neurons that may contribute to the neurological symptoms associated with gliomas. 
Due to intermingling of glioma cells and neurons it has been challenging to isolate and 
characterize neurons from glioma brain tissue while preserving complex neuronal morphology. 
To address this issue we developed a new mouse glioma model that allowed us to obtain a 
neuron specific gene expression profile, otherwise obscured by the predominantly large 
population of glioma cells within the tumor. In this thesis I use this model to test the hypothesis 
that infiltrating glioma cells induce phenotypic alterations in neurons that contribute to the 
neurological symptoms associated with glioma. 
The Camk2a-Ribotag mouse glioma model enabled us to isolate neuron specific transcripts from 
glioma brain tissue. The Ribotag mouse has a conditional HA-tagged ribosomal protein (Rpl22) 
that can be expressed upon Cre-recombination. Camk2a is specifically expressed in excitatory 
neurons, the Camk2a-Cre mouse induces Cre-recombination in the Ribotag mouse so that 
Camk2a+ neurons selectively express HA-tagged Rpl22. We used the Camk2a-Ribotag glioma 
model to isolate neuron specific ribosome bound transcripts to characterize neuronal alterations 
in glioma.  
 In chapter 2 of this thesis I describe how we developed and characterized the Camk2a-Ribotag 
mouse glioma model. We first obtained mouse glioma cells that have p53 deletion and 
overexpress PDGFRa, then we injected these cells in the Camk2a-Ribotag mouse and use this as 
our glioma model to extract neuron specific ribosome bound transcripts. This method is referred 
to as translating ribosome affinity purification (TRAP) which is used to obtain cell type specific 
translational profiles. Using this approach we identified alterations in neuronal gene expression, 
specifically we show that there is an upregulation of actin binding genes associated with 
dendritic spine morphology and a downregulation of synaptic genes associated synaptic 
regulation. We demonstrate that drebrin, an actin binding protein in dendritic spines, is 
upregulated in tumor brain synaptosomes, we also show a downregulation of dendritic spine 
density in HA-tagged neurons which suggests that these neuronal alterations contribute to 
synaptic dysfunction in our glioma model. 
Dendritic spines are dynamic structures that regulate synaptic function in response to diverse 
stimuli. mTOR signaling can regulate brain specific functions such as synaptic plasticity. 
Alterations in mTOR signaling can result in cognitive deficits, epilepsy and brain abnormalities 
that are associated with neurological disease. We hypothesized that mTOR regulates the 
neuronal alterations we identified in our glioma model. In chapter 3 of this thesis I describe how 
we tested this hypothesis by acutely inhibiting mTOR signaling with the ATP competitive 
inhibitor AZD8055 in the Camk2a-Ribotag mouse glioma model. Using TRAP we show that 
acute mTOR inhibition reverses many neuron specific alterations that occurs in the glioma 
infiltrated cortex, actin binding genes that were upregulated in tumor brains were downregulated 
after mTOR inhibition and synaptic genes that were downregulated in tumor brains were 
upregulated after mTOR inhibition. These results suggest that key neuron specific alterations are 
regulated by mTOR signaling in our glioma model. 
In chapter 4 of this thesis I describe how we used ribosome profiling to identify translational 
alterations in our Camk2a-Ribotag mouse glioma model. Ribosome profiling in an RNA 
sequencing based method that is used to measure translation efficiency by calculating the 
number of ribosomes per transcript. Using this approach we identified an upregulation in the 
translation of DNA methylation and demethylation gene ontologies. These results suggest that 
alterations in specific DNA methylation and demethylation gene ontologies are regulated at the 
level of translation and warrant further analysis of cell type specific translational alterations 
using ribosome profiling. 
The work described in this thesis demonstrates 1) use of the Camk2a-Ribotag mouse glioma 
model for the identification of neuron specific alterations, 2) neuron specific alterations include 
the upregulation of dendritic spine genes, downregulation of synaptic genes and downregulation 
of dendritic spine density, 3) acute mTOR inhibition reverses many of these neuronal alterations, 
4) ribosome profiling revealed the translational upregulation of epigenetic genes in our mouse 
glioma model. The findings described in this thesis provide the first characterization of neuron 
specific transcriptional and translational alterations in glioma infiltrated cortex that and provide 
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1.1 Glioma as a neurological disease and challenges associated with studying gliomas 
Glioma classification, standard of care, and survival 
Diffusely infiltrating gliomas are one of the most common primary brain tumors in adults 
(Weller, Wick et al. 2015). These types of brain tumors are classified based on histological and 
molecular features to guide treatment options (Louis, Perry et al. 2016, Masui, Mischel et al. 
2016). Standard of care for patients with glioma include surgical resection, followed by 
chemotherapy and radiotherapy (Stupp , Mason  et al. 2005, van den Bent, Snijders et al. 2012, 
Davis 2016). However, because these tumors diffusely infiltrate the brain, complete surgical 
resection is not possible and remaining tumor cells eventually result in recurrence.  
Gliomas are classified based on histological and molecular features which determine the 
World Health Organization (WHO) grade and influence the course of treatment. Histological 
assessment of glioma tissue analyzes the degree of mitotic activity, nuclear atypia, vascular 
proliferation and necrosis as well as the astrocytic and oligodendroglial features. Lower grade 
gliomas consist of grade I and II tumors, which have none to one of the histological features 
described above. Low grade tumors include diffuse astrocytoma and oligodendroglioma. The 
presence of mitotic activity determines grade III anaplastic astrocytoma tumors, and the presence 
of necrosis and vascular proliferation determines grade IV glioblastoma diagnosis (Wesseling, 
Kros et al. 2011).  
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Glioblastoma (GBM) is characterized as a high-grade tumor (grade IV) that generally 
arises as a de novo lesion that progresses rapidly despite standard of care therapy with survival 
ranging from 12-18 months. GBMs are more common in the older population with an average 
age of 64 years. However, despite aggressive treatment, glioma recurrence is inevitable which is 
believed to be a result of the invasiveness of tumor cells throughout brain tissue that makes 
complete surgical removal impossible (Cuddapah, Robel et al. 2014). Gliomas that are 
characterized as lower-grade gliomas (grade II or III) are slower growing lesions for which 
survival ranges from 3-10 years and more often affect young adults (Delgado-López, Corrales-
García et al. 2017). Despite the slower growing capacity of lower-grade glioma these tumors 
eventually progress to higher-grade tumors.  
Patients with diffusely infiltrating glioma have neurological deficits 
Symptoms prior to glioma diagnosis include headaches, seizures and cognitive deficits 
(Taphoorn and Klein 2004, Bosma, Vos et al. 2007, Miotto, Silva Junior et al. 2011, Bergo, 
Lombardi et al. 2016). After diagnosis, patients continue to present with these symptoms which 
generally get worse as a result of tumor growth and treatment effects resulting in a poor quality 
of life. Neurological symptoms include impaired working memory, decision making, verbal 
fluency and social cognition. Seizures and impaired neurological function are particularly 
debilitating in patients with lower-grade glioma that have a longer survival range and which are 
often refractory to anti-epileptic drugs (Vecht, Kerkhof et al. 2014).  
Gliomas are mostly localized to the cerebral cortex (frontal and temporal lobes), which 
explains the impairment in executive function, memory, emotion or concentration. Worsening of 
seizures and cognitive function is usually a sign of tumor progression which is attributed to the 
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diffuse infiltration of tumor cells in these brain regions (Bergo, Lombardi et al. 2015). However, 
very little is known about how infiltrating glioma cells affect cortical function, and virtually 
nothing is known about the phenotypic or functional alterations in cortical neurons at the 
infiltrative margins of glioma. 
Reactive plasticity as a response to slow growing glioma lesions 
Patients with low grade glioma (LGG) often have a pre-symptomatic period when glioma 
growth is taking place with no observable symptoms. In fact, gliomas can occupy a remarkably 
large volume of brain before they manifest clinical symptoms. This could be explained by the 
glioma cell infiltration induced adaptions in brain tissue which enable the preservation of neural 
function despite glioma cell infiltration. This concept is referred to as reactive plasticity which is 
a response mechanism by which the brain adapts to pathological stimuli resulting in the 
reorganization of neural circuits to preserve remaining function (Kong, Gibb et al. 2016). This 
concept has been studied in various neurological diseases including traumatic brain injury, stroke 
and is more recently being explored in low grade glioma (Desmurget, Bonnetblanc et al. 2007).  
Acute brain injuries include sudden insults such as stroke or traumatic brain injury which 
occur over the course of minutes. Progressive brain injuries slowly develop including 
neurodegenerative disease or low grade gliomas which develop over the course of years. One 
important difference between acute and progressive brain injuries is the functional recovery of 
the affected brain circuits and the associated cognitive process. Progressive brain injuries result 
in a much better recovery compared to acute brain injury, suggesting that slower developing 
lesions allow for reactive plasticity and the adaptive processes required to preserve function 
(Desmurget, Bonnetblanc et al. 2007).  
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Reactive plasticity in glioma has been studied primarily from a clinical perspective using 
intraoperative direct electrocortical stimulation (DES) which allows neurosurgeons to identify 
critical brain regions for specific functions by inhibiting the cortical area associated with a 
specific function (Kong, Gibb et al. 2016). These methods have identified cortical brain regions 
responsible for specific functions such as speech or movement (so called eloquent cortex). 
During subsequent surgical resections DES showed that the same brain region once responsible 
for a specific function is no longer critical for that function, providing compelling clinical 
evidence that reactive plasticity is continuously taking place at in glioma infiltrated cortex 
(Duffau 2014). Research on reactive plasticity has begun to study how acute and progressive 
brain injuries differentially influence plasticity (Kong, Gibb et al. 2016)  
Neuroplasticity occurs during development and in adults during which guidance cues for 
axonal sprouting guide brain development and dendritic and synaptic morphology are altered for 
making appropriate synaptic connections (Nudo 2013). The mechanisms involved in synaptic 
plasticity during development have been widely characterized and point to mechanisms 
including the alterations in the regulation of glutamate receptors as well as alterations in the 
morphology and function of dendritic spines. The actin cytoskeleton plays an essential role in 
dendritic spines, it can be regulated by synaptic inputs and adapts to modulate the morphology 
and function of dendritic spines during synaptic plasticity (Yuste and Bonhoeffer 2001, Lai and 
Ip 2013, Maiti, Manna et al. 2015, Hlushchenko, Koskinen et al. 2016, Kong, Gibb et al. 2016). 
However, plasticity following brain injury is less well understood but motivates efforts to 




Molecular characterization of glioma reveals gene expression profiles that identifies distinct 
glioma subtypes 
Molecular characterization of gliomas has identified genetic alterations found in brain tumor 
tissue that can predict patient prognosis, response to therapy and provide molecular markers for 
more accurate classification by clinicians (Masui, Mischel et al. 2016). Extensive 
characterization of GBM has contributed to the identification of distinct gene expression profiles 
including proneural, mesenchymal, neural, and classical subtypes (Nutt, Mani et al. 2003, Shai, 
Shi et al. 2003, Freije, Castro-Vargas et al. 2004, Phillips, Kharbanda et al. 2006, Parsons, Jones 
et al. 2008, The Cancer Genome Atlas Research 2008, Verhaak, Hoadley et al. 2010, Zong, 
Verhaak et al. 2012, Brennan, Verhaak et al. 2013). The proneural GBM subtype is characterized 
by genetic alterations that result in overexpression of PDGFRα, IDH1 mutations, and p53 
mutation or loss of heterozygosity. Proneural tumors are also characterized by oligodendrocyte 
developmental genes such as Olig2 and PDGFRα (Verhaak, Hoadley et al. 2010).  However, due 
to the cellular heterogeneity of gliomas, studies have detected different GBM subtypes from 
distinct biopsies from the same patient suggesting that this classification system is variable and 
depends on the cellular composition of the tissue sampled (Sottoriva, Spiteri et al. 2013, Gill, 
Pisapia et al. 2014, Patel, Tirosh et al. 2014)  
Molecular characterization of the infiltrative margins of glioma   
Most of the molecular characterization in glioma has come from analysis of the tissue 
taken from the tumor core, since this is generally what is removed during surgery. Our lab has 
shown that MRI-localized biopsies from the contrast enhancing  tumor core have distinct gene 
expression profiles from MRI-localized biopsies from the non-enhancing infiltrative margins of 
glioma (Gill, Pisapia et al. 2014). This is likely influenced by the cellular composition of each 
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tissue sample which is reflected in the gene expression profile that defines a GBM subtype. 
Tissue from the infiltrative margins contains a mixture of glioma cells and non-neoplastic cells, 
including microglia, astrocytes, oligodendrocytes and neurons.  Identifying the molecular and 
cellular alterations at the infiltrative margins is of great clinical importance since this tissue is 
what gets left behind after surgery and will eventually give rise to tumor recurrence.  
Recent research has assessed microglia and astrocytes found in glioma brain tumor tissue 
since these cells can contribute to glioma cell proliferation and invasion and can potentially be 
targeted to inhibit tumor growth (O'Brien, Howarth et al. 2013, Gutmann 2015, 
Hambardzumyan, Gutmann et al. 2015, Placone, Quiñones-Hinojosa et al. 2016). As discussed 
below, neurons are implicated in many of the clinical manifestations of glioma (including 
seizures and cognitive dysfunction) and have also recently been implicated in regulating glioma 
cell proliferation (Venkatesh, Johung et al. 2015, Venkatesh, Tam et al. 2017). However, the 
transcriptional and translational alterations that occur in neurons in the glioma infiltrating cortex 
has not been well characterized. 
Molecular alterations of neurons in glioma remain an understudied problem 
Research on the interactions between glioma cells and neurons has focused on the effects of 
glutamate on neurotoxicity and seizure induction (Buckingham, Campbell et al. 2011, Campbell, 
Buckingham et al. 2012, Savaskan, Fan et al. 2015). This research has primarily focused on the 
levels of glutamate found in the glioma microenvironment which result in neuronal alterations 
that contribute to seizure activity. However, the alterations in neurons themselves within glioma 
have not been studied. As discussed below, neuronal activity has been implicated in regulating 
glioma cell proliferation which may contribute to glioma growth (Venkatesh, Johung et al. 2015, 
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Johung and Monje 2017, Venkatesh, Tam et al. 2017). Gliomas exhibit a histological feature 
referred to as perineuronal satellitosis, where tumor cells closely encircle neuronal cell bodies in 
brain tissue (figure 1) (Claes, Idema et al. 2007). The physical proximity of these distinct cell 
types suggests a close relationship between tumor cells and neurons that has not been explored.  
The relationship between glial cells and neurons has been explored in normal brain where 
satellite cells, including astrocytes and oligodendrocytes, closely surround neuronal soma in the 
cerebral cortex and hippocampus (Sarnat and Flores-Sarnat 2013). This histologic feature occurs 
in normal brain, and has been shown to increase during neurologic disease. Satellite glial cells 
are generally adhered to normal neurons, but in epilepsy they are shown to surround dying 
neurons. It has been proposed that the function of satellite glial cells is to protect neurons during 
suboptimal conditions, such as dysregulated neuronal activity in epilepsy. One way satellite glial 
cells can do this is through adhesion molecules on glia (β2 subunit of Na/K ATPase pump) 
which helps mediate ion homeostasis to maintain a resting membrane potential (Sarnat and 
Flores-Sarnat 2013). Alternatively, satellite glial cells can contribute to dysregulated neuronal 
activity, one way they could do this is by dysregulating ion homeostasis which can result in 
neuronal membranes to become more easily depolarized. 
Further characterization of the effects of glioma cells on neurons is essential as this may 
underlie the neurological deficits associated with glioma and can provide therapeutic alternatives 
for these symptoms. However, to identify alterations in neurons within glioma infiltrated cortex, 
we must develop methods to overcome the challenges imposed by the complex cellular 




 1.2 Identification of distinct cell types in brain tissue 
Complex cellular composition contributes to challenges in dissociating specific cell types in 
brain tissue 
Brain tissue is composed of multiple cell types including neurons, astrocytes, 
oligodendrocytes, microglia and progenitor cells. These different cell types are physiologically 
and structurally entangled. Neurons have processes that allow them to send and receive signals 
for proper functional connections in neural circuits across brain regions. Neurons rely on other 
cell types in brain tissue to form intricate neural circuits (Pekna and Pekny 2012). For example, 
oligodendrocytes are closely positioned on the axonal processes of neurons for facilitating signal 
transmission, astrocytic endfeet form part of the neuronal synapse and work to regulate synaptic 
transmission, microglia help to clear pathogens and toxic cell debris when needed (Allen and 
Barres 2009, Pfrieger 2010). Astrocytes can respond to neurotransmitter release by modulating 
calcium signals that influence neuronal excitability and ultimately modulate synaptic plasticity 
(Ota, Zanetti et al. 2013, Haydon and Nedergaard 2015, Verkhratsky and Nedergaard 2017). 
Together, these cell types function to respond to internal and external signals such as brain injury 
and learning and memory (Pekna and Pekny 2012).  
Distinct cell types in brain tissue are intermingled among one another making it difficult to 
technically separate cells for further characterization. Neurons are particularly subject to this 
constraint due to their intricate morphology. Neuronal processes have been shown to contain 
ribosomes and mRNAs that are transported via RNA granules which contribute to localized 
protein synthesis during development and plasticity (Kiebler and Bassell 2006). Selective 
mRNAs are enriched in neuronal dendrites and their expression is thought to be locally regulated 
as a result of synaptic activity (Doyle and Kiebler 2011). Due to the information contained 
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within neuronal processes it is essential to use methods that preserve rather than disturb neuronal 
processes as a result of physically separating neurons for molecular characterization. 
Methods used to study specific cell types in brain tissue 
Characterization of distinct cell types in brain tissue generally begins by 
immunohistochemical staining and morphological assessment. Isolation of specific cell types 
from brain tissue has allowed for further molecular characterization. However, due to the limited 
number of genes that can be assessed at one time, next generation sequencing has emerged as a 
prominent tool that can be used to characterize specific brain cell types based on their gene 
expression profile (Lein, Hawrylycz et al. 2007, Cahoy, Emery et al. 2008, Hawrylycz, Lein et 
al. 2012, Zhang, Chen et al. 2014, Tasic, Menon et al. 2016).  
Recently, single cell sequencing has enabled the characterization of individual cells from 
brain tissue (Zeisel, Muñoz-Manchado et al. 2015, Földy, Darmanis et al. 2016, La Manno, 
Gyllborg et al. 2016, Poulin, Tasic et al. 2016, Cuevas-Diaz Duran, Wei et al. 2017, Picardi, 
Horner et al. 2017). Methods used to isolate specific cell types include enzymatic dissociation 
which incubates brain tissue with a proteolytic enzyme that releases individual cells from bulk 
tissue. Further isolation of specific cell types can be performed by fluorescence-activated cell 
sorting (FACS) which relies on the cell type of interest expressing a marker for which an 
antibody against that marker is used to sort cells via a flow cytometer.  Additionally, mechanical 
dissociation and laser capture microdissection discreetly dissect tissue from a brain region of 
interest and further purify the tissue to remove other cell types typically by immunopanning 
(Garrido-Gil, Fernandez-Rodríguez et al. 2017, Olah, Patrick et al. 2018). These methods are 
effective in isolating cell types that well circumscribed without long processes intertwined within 
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brain tissue. However the physical disruption that the tissue undergoes during these procedures 
has the risk of damaging neuronal axons and dendrites and potentially losing the critical 
information contained within them.  
Challenges associated with studying specific cell types in brain tissue 
Bulk tissue is subject to enzymatic digestion and mechanical isolation when isolating 
individual cells or a population of cell types. There are multiple caveats associated with these 
types of methods that should be considered when assessing results from this field of research 
including 1) enzymatic dissociation induces mechanical stress that influences gene expression, 2) 
gene expression from cell types that are less abundant, or harder to isolate, in the tissue may not 
be well represented, 3) microdissection and enzymatic dissociation can damage neuronal 
processes and deplete RNAs that are found in these compartments (Poulin, Tasic et al. 2016).  
Molecular profiling of less abundant cell types in glioma make it difficult to isolate cells 
such as neurons, and obtain gene expression profiles that reflect their alterations in brain tumor 
tissue were tumor cells are the predominant cell type. Our laboratory has contributed to an effort 
that implemented a computational algorithm that can predict cellular composition based on cell 
type specific markers (Gill, Pisapia et al. 2014, Gonzalez, Sims et al. 2014).  
Single cell sequencing has been applied in glioma and confirms the cellular heterogeneity 
observed between and within different glioma tumors (Darmanis, Sloan et al. 2017, Tirosh and 
Suvà 2017). This paper compared gene expression profiles peritumoral cells between tumor core 
and peripheral regions and did not find a difference among neuronal gene expression (Darmanis, 
Sloan et al. 2017). This finding could be confounded by the fact that both regions where neurons 
were taken from were affected by the tumor resulting in transcriptionally similar profiles and 
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thus a significant change in gene expression wouldn’t be detected. Additionally, the enzymatic 
dissociation method used to assess neuronal alterations could have damaged neuronal process 
and resulted in a loss of critical information contained within these structures. Thus, there is a 
need for better methods that carefully characterize neurons from glioma brain tissue without 
damaging neuronal cell morphology. 
The Ribotag system as a tool to profile cell type specific translation in brain tissue 
Transgenic mouse models have been developed to enable the isolation and extraction of 
cell type specific signatures from brain tissue (Heiman, Schaefer et al. 2008, Heiman, Kulicke et 
al. 2014).  For example, the Ribotag mouse harbors a floxed ribosomal protein (Rpl22) followed 
by an identical HA-tagged version of Rpl22 (Sanz, Yang et al. 2009). Expression of the HA-
tagged version of Rpl22 depends on Cre recombination, in the absence of Cre expression only 
endogenous Rpl22 is expressed. This system allows for the immunoprecipitation of HA-tagged 
ribosomes using an anti-HA antibody and isolating their associated translating mRNAs in the 
cell type of interest. It also allows for the identification of specific cell types from 
immunohistochemical staining using an anti-HA antibody.  
The Ribotag mouse has been crossed with multiple cell type specific Cre transgenic mice 
resulting in expression of the HA-tagged ribosomes in a cell type of interest, this method is 
referred to as translational ribosome affinity profiling (TRAP) (Doyle, Dougherty et al. 2008, 
Heiman, Schaefer et al. 2008, Sanz, Evanoff et al. 2013, Soden, Miller et al. 2016). This 
methodology has also been used with bacterial artificial chromosome (BAC) transgenic mice 
which express an EGFP-L10a ribosomal transgene that enables immunoprecipitation of GFP-
tagged ribosomes and identification of the translating mRNAs in a cell type of interest. The 
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difference between the Ribotag and the BAC transgenic mice is that the EGFP-tagged ribosomal 
protein L10a is driven by an exogenous promoter that can result in different levels of EGFP-
L10a and wildtype L10a which can affect the enrichment of cell type specific mRNAs (Kapeli 
and Yeo 2012). Instead, the Ribotag allele (Rpl22-HA) is expressed under the control of the 
endogenous promoter which results in cell type specific expression of the HA-tag.  
In particular, the Ribotag mouse has been used to identify transcriptional and translational 
alterations in glioma cells using one of our glioma mouse models (Gonzalez, Sims et al. 2014). 
We have also shown that the Ribotag mouse when crossed with Camk2a-cre mouse can be used 
to label and isolate Camk2a+ neuronal transcripts for molecular characterization in non-tumor 
bearing brain (Hornstein, Torres et al. 2016). Camk2a is a calcium binding protein, primarily 
expressed in brain and enriched in principal neurons which are found throughout the cortex 
(Tsien, Chen et al. 1996, Dragatsis and Zeitlin 2000). The Camk2acre mouse allows us to 
selectively target cre-mediated recombination specifically to principal neurons which are 
excitatory neurons located in the cortex. In combination with the Ribotag mouse, our model can 
be used for the extraction of neuron derived ribosomes and the transcripts that are bound to them. 
Molecular characterization of these transcripts by RNA sequencing then provides a translational 
profile of neuron specific ribosome bound transcripts which can be used for the analysis of 
neuronal alterations in neurological disease.  
Mouse models used to study glioma  
Many different types of mouse glioma models have been developed to aid in the 
identification of genetic alterations and molecular mechanisms underlying tumor growth. These 
models are also used for testing potential therapeutic drugs. Genetically engineered mouse 
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models are useful for understanding the mechanisms that drive tumor growth. Xenograft models 
are derived from human glioma cells and transplanted to immune compromised mice (Huszthy, 
Daphu et al. 2012). Both transgenic and xenograft models can be useful in studying glioma 
growth and identifying potential therapeutic targets, however tumors from xenograft models tend 
to grow as a well circumscribed balls rather than diffusely invading surrounding brain tissue. In 
order to study the effects of glioma cells on neighboring cells such as neurons it would be 
essential that the glioma model being used to study these effects replicated the infiltrative 
patterns seen in human gliomas.  
Retrovirally induced glioma mouse model driven by PDGF overexpression and p53 deletion 
Our laboratory has developed several different mouse glioma models that recapitulate the 
histological and molecular hallmarks of human glioma. Our glioma models rely on the 
stereotactic delivery of a retrovirus expressing platelet derived growth factor (PDGF) and Cre-
recombinase to the subcortical white matter of p53 or PTEN floxed mice. This leads to 
retrovirally infected cells expanding to develop high grade glioma driven by PDGFB 
overexpression and p53 or PTEN deletion in retrovirally infected oligodendrocyte progenitors 
(OPCs) (Lei, Sonabend et al. 2011, Gonzalez, Sims et al. 2014, Sonabend, Bansal et al. 2014, Lu, 
Chen et al. 2016). These glioma models also harbor a cherry luciferase floxed allele that upon 
Cre expression in transformed OPCs expresses the luciferase reporter enabling bioluminescent 
imaging of tumor growth.  
We have also delivered a retrovirus expressing PDGFA and Cre-recombinase to p53 floxed 
mice which result in the formation of low grade glioma tumors. Retrovirally infected cells 
overexpress PDGFA and expand to form a diffusely infiltrating tumor (unpublished). 
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Histological characterization of our PDGFA driven tumor model show diffuse infiltration of 
glioma cells into surrounding brain tissue and perineuronal satellitosis in cortical regions. Our 
model shows a high degree of infiltrating tumor cells into cortical brain tissue were neurons are 
intermingled with tumor cells, making this model ideal for us to use to study the effects of 
glioma cells on neurons. Furthermore, we isolated tumor cells from our PDGFA driven tumor 
model and injected them into Camk2a-Ribotag mice which enabled us to isolate Camk2a+ 
neuron derived ribosome bound transcripts from brain tissue during glioma growth 
(unpublished). These mice develop diffusely infiltrating gliomas that closely resemble human 
low grade glioma. Thus, our glioma mouse model serves as a tool for us to study the effects of 
glioma cells on neurons.  
Our Camk2a-Ribotag mouse glioma model enables us to determine alterations in ribosome 
bound RNAs, but it is not able to tell us alterations in non-ribosome bound messages. In our 
model we calculate the enrichment of neuron-specific genes by taking the ratio of neuron 
specific ribosome bound RNAs over homogenate RNAs. The homogenate contains ribosome 
bound and non-ribosome bound RNAs, taking the ratio of IP/homogenate could be considered a 
limitation in our model since the IP only includes ribosome bound RNAs. Additionally, by 
taking the right frontal lobe of tumor-bearing brain tissue we could be losing the spatial 
distribution of alterations. Neurons could regulate their expression patterns in a distinct form 
depending on their location relative to the location of the tumor. Despite these limitations, our 
model has provided evidence for the first time about the molecular alterations in neurons within 





Current research on non-neoplastic cells found in glioma brain tissue  
It is now recognized that similar to other types of cancer, brain tumors have 
microenvironments containing non-neoplastic cells that can contribute to tumor progression and 
response to treatment. This has motivated researchers to focus on the role of microglia and 
astrocytes in glioma progression. Microglia have been investigated for their role in producing 
paracrine factors and chemokines that stimulate tumor cell growth and migration (Coniglio and 
Segall 2013, Wei, Gabrusiewicz et al. 2013, Hambardzumyan, Gutmann et al. 2015).  In glioma, 
astrocytes can promote proliferation and invasion of tumor cells by releasing cytokines and 
chemokines that activate an inflammatory response (Guan, Hasan et al. 2018). Astrocytes within 
glioma are also involved in the response to brain injury or neurological disease (Liddelow and 
Barres). As a result of injury or disease, astrocytes become reactive, meaning their morphology 
is altered and they can proliferate around the site of injury (Buffo, Rite et al. 2008). In glioma, 
astrocytes are also being considered for their contribution to tumor progression which can shed 
light on novel therapeutic targets (Katz, Amankulor et al. 2012).  
Much of the research on neurons within glioma has focused on the effects of excess 
glutamate on neurotoxicity and seizure induction (de Groot and Sontheimer 2011, Huberfeld and 
Vecht 2016). Tumor cells release excess glutamate that binds NMDA receptors and induces an 
influx of calcium in neurons that results in cell death. The loss of neurons then presumably 
allows tumor cells to move into the empty space to propagate their growth (Sontheimer 2008). 
High glutamate levels have also been attributed to seizure induction, since seizures are generally 
characterized by an imbalance of excitatory and inhibitory transmission (Buckingham, Campbell 
et al. 2011, Campbell, Buckingham et al. 2012).  
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The effects of neuronal activity on other cell types in the brain has been explored through 
optogenetic approaches which showed that neuronal activation can induce progenitor cell and 
glioma cell proliferation suggesting that neuronal activity may contribute to glioma growth 
(Venkatesh, Johung et al. 2015, Venkatesh, Tam et al. 2017). Together these studies highlight 
multiple interactions between neurons and glioma cells but these studies have not taken a 
comprehensive approach to characterizing the alterations in neurons within the glioma 
microenvironment. To begin to investigate the effects of proliferating progenitor cells on neurons 
in vivo we assessed neuronal gene expression profiles at the level of transcription and 
translation.   
1.3 Transcriptional and translational analysis in brain tissue 
Translational regulation through mTOR signaling plays a key role in determining gene 
expression  
Early findings that cancer cells have increased numbers of ribosomes and require 
increased protein synthesis has prompted researchers to identify the molecular mechanisms 
underlying translational regulation in cancer. Translation of mRNAs controls multiple cellular 
processes including metabolism, cell growth and proliferation (Ruggero 2013). Translational 
regulation serves as a cell’s immediate response to alterations in its environment by providing 
adaptive changes in gene expression (Bhat, Robichaud et al. 2015). Translation is an 
energetically costly process in cells, as a result translation is tightly controlled to preserve cell 
resources.  
mTOR signaling is known to regulate translation by controlling the expression of genes 
involved in various steps of protein synthesis (Ruggero 2013). Upregulation of the mTOR 
pathway can modulate protein synthesis while enabling cancer cells to grow and proliferate 
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(Silvera, Formenti et al. 2010). There are multiple pharmacological inhibitors that target mTOR 
signaling and have been used to investigate translation regulation, one study revealed that 
translationally regulated genes are associated with cell invasion, proliferation, and metabolism in 
pancreatic cancer cells while another study identified the mTOR regulated genes to be mainly 
components of the translational machinery in mouse embryonic fibroblasts (Hsieh, Liu et al. 
2012, Thoreen, Chantranupong et al. 2012, Ruggero 2013).  mTOR signaling has also been 
implicated in neuronal translation during synaptic plasticity in learning and memory processes 
(Takei and Nawa 2014). Additionally, dysregulation of mTOR in neurological disease is thought 
to contribute to brain dysfunction via alterations in translational regulation (Gal-Ben-Ari, 
Kenney et al. 2012). 
Ribosome profiling as a tool for studying translation 
Transcriptional analysis has provided information about the abundance of mRNAs available 
for translation. However, it has been shown that mRNA levels are not concordant with protein 
levels, suggesting that there is further regulation of protein synthesis (Maier, Güell et al. 2009). 
This has prompted researchers to focus on translational regulation which can be determined from 
the number of actively translated transcripts measured by the ribosome density per transcript. 
The translation of a specific mRNA can be obtained by polysome profiling which is a technique 
that isolates ribosome bound transcripts (polysomes) through sucrose gradient centrifugation 
under the assumption that a shift in translational status is determined by a shift of an mRNA in 
the polysomal gradient. These sucrose fractions were then analyzed by northern blot or qPCR 
(Mašek, Valášek et al. 2011, King and Gerber 2016).  
Ribosome profiling has emerged as a technique in which short ribosome protected mRNA 
fragments are isolated and sequenced. Ribosome density is then used as a proxy for the rate of 
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translation (Brar and Weissman 2015). Translation rate can then be used to measure translation 
efficiency from individual genes from the entire genome (Ingolia, Ghaemmaghami et al. 2009). 
Translation efficiency is referred to as the ratio of the translation rate (ribosome density per 
transcript) to the abundance of a specific transcript. Ribosome profiling serves as a method to 
obtain the rate of translation and position of a ribosome on a transcript, providing information 
about the location of ribosomes which can tell us if ribosome bound transcripts are being 
translated or if ribosomes are stalled.  
Translational regulation in neurological disease and glioma 
Translation has been studied in neurons particularly during synaptic plasticity for 
cognitive processes. Dysregulation of mTOR signaling in neurological diseases such as Tuberous 
Sclerosis Complex (TSC), fragile X syndrome, Retts syndrome, and neurodegenerative diseases 
suggest that mTOR plays a role in translational regulation (Gal-Ben-Ari, Kenney et al. 2012). 
Neurons implement translational regulation mechanisms for specialized compartments such as 
axons and dendrites. Local translational regulation is essential for neurons because in some cases 
proteins can be harmful if found at other cellular compartments and also because it is required 
for rapid and localized responses to synaptic stimuli (Di Liegro, Schiera et al. 2014).   
A study that analyzed translation in a glioma mouse model identified that there is 
increased translation efficiency for genes that promote cell proliferation while genes associated 
with synaptic proteins had decreased translation efficiency (Helmy, Halliday et al. 2012). This 
study claimed that the decreased translation of synaptic proteins was likely a result of the lack of 
neuronal differentiation of Olig2+ glioma cells. To assess translation this study used a BAC 
transgenic mouse that expresses the large ribosome unit protein L10a with GFP under the control 
of the Olig2 BAC promoter and using TRAP methodology calculated translation efficiency by 
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taking the ratio of the immunoprecipitated (for GFP) transcripts over the total transcripts 
(determined from FACS cell sorting for GFP). The methodology used in this study has a few 
limitations 1) Olig2 is expressed in untransformed glial progenitors 2) the number of transcripts 
determined from immunoprecipitation does not yield the density of ribosomes per transcript, 
which is required to calculate translation efficiency.  
Our laboratory recently contributed to a study that assessed translational regulation using 
a different approach. We delivered a PDGFB-cre expressing retrovirus to Ribotag mice which 
induces expression of the ribosomal protein (Rpl22) tagged with HA selectively in retrovirally 
infected glial progenitors. We then performed RNA sequencing and ribosome profiling on 
homogenate and HA-immunoprecipitated mRNAs to measure total transcript levels across cell 
types and transformed glial progenitor transcript levels, respectively. This study determined that 
while the translation rate for genes enriched in transformed glial progenitors had increased, the 
translation efficiency of these genes is decreased (Gonzalez, Sims et al. 2014). These findings 
suggest that glioma cells are likely saturated with transcripts that they can no longer efficiently 
translate, suggesting that glioma cells are under a high degree of translational regulation. 
Our lab also characterized translational regulation in normal brain tissue using the 
Ribotag mouse to isolate neuron specific transcripts. We assessed the efficiency of a new 
ribosome profiling strategy to detect changes in gene expression when pharmacologically 
inhibiting mTOR signaling. We determined that the novel ribosome profiling strategy is efficient 
and that canonical mTOR targets are promptly downregulated after mTOR inhibition in normal 
brain (Hornstein, Torres et al. 2016).  Translational regulation plays an important role in glioma, 
which merits further characterization of the mechanisms involved in translation control. mTOR 
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signaling is often involved in driving glioma growth and its role in translation may provide a 
mechanistic understanding of how mTOR contributes to tumor growth.  
1.4 mTOR signaling in neurological disease  
Upstream and downstream of mTOR signaling 
mTOR is a protein kinase and a component of a complex signaling cascade that integrates 
signals from growth factors and nutrients to regulate essential cell functions including cell 
growth, proliferation, differentiation and translation (figure 1.2)(Takei and Nawa 2014). mTOR 
activity is regulated through the PI3K/AKT pathway which is negatively regulated by PTEN and 
TSC1/2. mTOR exists in two multi-protein complexes, mTORC1 and mTORC2. mTORC1 can 
be activated by growth factors, amino acids, neurotransmitters, hormones and generally responds 
to cell energy status, hypoxia, and other types of stressors (Takei and Nawa 2014). mTORC2 can 
be activated by growth factors as well, however this seems to be context dependent (Oh and 
Jacinto 2011). 
mTORC1 regulates the activity of S6 kinase and elongation binding proteins (4EBPs), 
resulting in the phosphorylation S6K1 and 4EBP1. Upon mTOR activation S6K1 is activated and 
phosphorylates ribosomal protein S6 (pS6), 4EBP is phosphorylated (p4EBP1) and 4EBP1 is 
disinhibited thereby enabling translation (Guertin and Sabatini 2009). Recent evidence has 
shown that the translation of TOP mRNAs, which contain a 5’-terminal oligopyrimidine 
sequence (TOP) and are specific for components of the translational machinery, is regulated 
through 4EBP phosphorylation (Thoreen, Chantranupong et al. 2012). The mTOR signaling 
pathway has feedback loops that are in place to maintain homeostatic regulation. mTOR is 
negatively regulated by suppressing PI3K through S6K (Guertin and Sabatini 2009). mTORC2 
regulates Akt phosphorylation (Ser473) which is needed for maximal Akt activity, which places 
21 
 
mTOR both upstream and downstream of Akt (Efeyan and Sabatini 2010). Disruption of the 
mTOR pathway can have detrimental effects during development and in neurological disease 
which make mTOR essential for normal brain function.  
mTOR signaling is required for normal brain function 
mTOR is involved in brain development including dendritic development, axon guidance, 
learning and memory, and in neuronal repair after injury (Curatolo and Moavero 2013). mTOR 
activation is dependent upon neuron receptor and channel activation that regulate neuronal 
translation(Takei and Nawa 2014).  Because of the role of mTOR in regulating translation, 
mTOR activity can modulate synaptic plasticity and has become a signaling pathway of interest 
for developmental processes and in many neurological diseases (Hoeffer and Klann 2010).  
Dysregulated mTOR signaling is an underlying cause for several neurological disorders 
Dysregulation of the mTOR pathway generally results in the upregulation of mTOR 
activity that is seen tuberous sclerosis complex disease (TSC), focal cortical dysplasia, and 
epilepsy (Lipton and Sahin 2014, Citraro, Leo et al. 2016). Upregulated mTOR activity results in 
enlarged neurons and abnormal cortical organization which is thought to contribute to the 
pathology of some neurological diseases. Several mouse studies have shown that seizures 
resulting from dysregulated mTOR activity can be prevented and inhibited with the mTOR 
inhibitor rapamycin, suggesting the potential use of mTOR inhibitors for seizures in other 
neurological disorders (Meikle, Talos et al. 2007, Zeng, Xu et al. 2008) (Huang, Zhang et al. 
2010, Guo, Zeng et al. 2013).  
In TSC, either TSC1 or TSC2 function is compromised resulting in direct upregulation of 
mTOR activity (Crino 2011). TSC results in seizures, benign brain tumors and other neurological 
deficits. The mTOR inhibitor everolimus is clinically approved to treat brain tumors and seizures 
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in TSC  (Krueger , Care  et al. 2010, Krueger Darcy, Wilfong Angus et al. 2013, French, Lawson 
et al. 2016). Because dysregulated mTOR signaling is seen in glioma and in seizures, inhibiting 
mTOR signaling in glioma would be an efficient way of targeting one pathway that affect both 
glioma growth and seizures associated with tumor growth (Huberfeld and Vecht 2016). 
Together, these studies show that targeting mTOR upregulation in neurological disease can 
inhibit neurological deficits.  
Alterations in PTEN also result in upregulated mTOR activity that has been shown in in 
autism. Autism results in impaired social and restrictive behaviors that appear during 
development. These symptoms have been associated with abnormal synapses including increased 
dendritic spine density (Sato 2016). mTOR inhibition in mouse models of autism have shown to 
ameliorate some of the synaptic alterations including decreasing dendritic spine density (Tang, 
Gudsnuk et al. 2014). Fragile X syndrome (FXS) is caused by loss of function mutations in the 
RNA binding protein fragile X mental retardation protein (FMRP) which result in mental 
retardation, cognitive impairment, seizures and autism (Sharma, Hoeffer et al. 2010). FMRP 
selectively binds mRNAs, specifically during transport to synapses, and inhibits their translation, 
therefore loss of FMRP function results in increased translation (Zalfa, Adinolfi et al. 2005). 
Since FXS is characterized by excessive translation, and increased mTOR activity is seen in FXS 
brains, mTOR has become a plausible mechanism driving increased translation. mTOR 
inhibitors have been shown to target some of the symptoms in FXS mouse models which is 
thought to occur via inhibition of translation (Sharma, Hoeffer et al. 2010, Sato 2016). Overall 
mTOR inhibition in neurological disease has shown promising results and motivates future 
studies to identify the mechanisms underlying these effects as well as the effects of mTOR 




Inhibiting mTOR signaling in glioma as an anti-tumor therapy has had limited effects 
Upregulated mTOR signaling is a frequent event in glioma that results from 
dysregulation in one or more upstream modulators of downstream effectors of mTOR (Akhavan, 
Cloughesy et al. 2010, Fan and Weiss 2012). Upregulated mTOR activity contributes to glioma 
cell proliferation and survival which has driven research to test the potential of mTOR inhibitors 
to inhibit glioma growth. Unfortunately mTOR inhibitors in glioma have had limited success 
which is most likely due to the fact that that mTOR inhibition is usually overcome since mTOR 
signaling is such a central component in maintaining cell survival. Alternatively, mTOR 
inhibitors that have been tested may not fully target all mTOR functions that drive tumor growth 
resulting in modest effects. This has driven the development of novel mTOR inhibitors that 
better target mTOR functions. 
Rapamycin is a macrocyclic antibiotic produced by soil bacteria. Rapamycin is an 
allosteric inhibitor of mTOR that targets mTORC1, it does so by binding to FKBP12, a cytosolic 
protein which then binds to mTOR in a region that is adjacent to the catalytic site (Efeyan and 
Sabatini 2010). However, studies have shown that rapamycin partially targets mTORC1 
functions, mainly affecting S6 kinase activity without affecting 4EBP (Feldman, Apsel et al. 
2009, Thoreen, Kang et al. 2009). mTORC2 regulates Akt phosphorylation (Ser473) and is  
insensitive to rapamycin. To target more downstream mTOR effectors than allosteric mTOR 
inhibitors, novel ATP-competitive mTOR inhibitors have been developed. ATP-competitive 
inhibitors bind to the active site of the mTOR kinase and inhibit the activity of both mTOR 
complexes. ATP-competitive inhibitors have been shown to target both S6 and 4EBP making 
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them more suitable compounds for analyzing complete inhibition of mTOR activity (Chresta, 
Davies et al. 2010).  
The innate cellular complexity in glioma has made it difficult to identify gene expression 
profiles in less abundant cell populations that are intermingled among tumor cells. The Camk2a-
Ribotag approach described in chapter 2 allowed us to reveal translational alterations in neurons 
from the glioma infiltrated cortex that have not been identified before. In chapter 3 I describe 
how inhibiting mTOR signaling for 6 hours reversed several of the glioma induced translational 
alterations in neurons. In chapter 4 I used ribosome profiling to identify translational alterations 
in homogenate glioma tissue. The work described in this thesis provides evidence for how a 
novel glioma mouse model can be used to identify otherwise undetected neuronal signatures and 
hopefully serve as a tool for further characterization of the neuronal alterations in glioma that 





























Figure 1.1: Mouse diffusely infiltrative glioma. HE from  mouse tumor 
cortex, close up image shows neuronal soma surrounded by tumor cells 
(perineuronal satellitosis).  
B 
Figure 1.2: mTOR signaling pathway. Upstream and downstream 




A new diffusely infiltrating glioma mouse model reveals neuronal alterations 
in the brain tumor microenvironment 
 
2.1 Introduction 
Gliomas are debilitating brain tumors for which patients present with neurological 
impairments during the course of the disease. Neurological impairments can be a result of tumor 
progression and can lead to a poor quality of life for patients with glioma. Gliomas are diffusely 
infiltrating brain tumors in which tumor cells invade surrounding brain tissue and intermingle 
with non-neoplastic cells including neurons. Patients with glioma often present with seizures and 
impaired cognitive function that worsen as tumor infiltration increases (Taphoorn and Klein 
2004, Miotto, Silva Junior et al. 2011, Bergo, Lombardi et al. 2015). Dysregulated neuronal 
activity has been demonstrated to contribute to seizures and impaired cognitive function in 
patients with glioma (Meyers 2002, Bosma, Vos et al. 2007, Buckingham, Campbell et al. 2011). 
However, molecular characterization of neurons within the glioma infiltrated cortex has been 
understudied.  
Human gliomas have been extensively characterized by gene expression profiles 
(Verhaak, Hoadley et al. 2010, Brennan, Verhaak et al. 2013), however most of this work has 
focused on the core of the tumor which is predominately composed of glioma cells. As a result, 
these studies have not been able to assess the gene expression profiles of less abundant cell types 
in gliomas such as neurons. Our laboratory characterized the glioma infiltrative margins using 
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RNA sequencing and determined that it is mainly composed of non-neoplastic cells such as 
neurons and oligodendrocytes (Gill, Pisapia et al. 2014), providing further evidence for the 
intermingling of tumor cells and non-neoplastic cells in the brain tumor microenvironment. 
Recently, the development of single cell sequencing has been able to isolate individual cells and 
generate single cell gene expression profiles from glioma brain tissue. A recent study used single 
cell RNA sequencing from human glioblastoma tissue but found no difference between neurons 
from the tumor core compared to those from the peritumoral area (Darmanis, Sloan et al. 2017). 
However, these findings may be confounded by the harsh methods used to dissociate glioma 
tissue in order to isolate neurons which results in mechanical damage that can induce  
transcriptional alterations or it can damage neuronal processes and deplete information that is 
enriched in these subcellular compartments (Poulin, Tasic et al. 2016). 
Previous studies have also used cell sorting or enzymatic dissociation methods to isolate 
cells and generate cell type specific gene expression profiles from normal brain (Cahoy, Emery 
et al. 2008, Doyle, Dougherty et al. 2008, Zhang, Chen et al. 2014, Tasic, Menon et al. 2016). 
Enzymatic dissociation and cell sorting introduce mechanical stress that can induce 
transcriptional alterations and damage cells with complex cellular morphology (Poulin, Tasic et 
al. 2016, Tirosh and Suvà 2017) . Neurons have complex cellular morphologies that are sensitive 
to currently used dissociation methods and thus information encoded in neuronal processes may 
have gone undetected in a recent study (Darmanis, Sloan et al. 2017). Neuronal processes 
contain ribosomes and mRNAs that are transported via RNA granules specialized for localized 
protein synthesis during neuronal plasticity (Kiebler and Bassell 2006). These transcripts can get 
lost during tissue dissociation resulting in a loss of the information encoded in these subcellular 
compartments. Therefore, there is a need to develop methods that can dissociate glioma brain 
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tissue while preserving complex neuronal morphology so as to isolate neuronal transcripts from 
subcellular compartments such as axons and dendrites. 
Due to the intermingling of different cell types in brain tissue it has been difficult to 
physically isolate and assess the molecular characteristics of specific cell types. To address this 
issue, our laboratory has shown that the Ribotag mouse can be used to selectively label and 
identify Camk2a+ neuronal transcripts for transcriptomic and translational analysis (Hornstein, 
Torres et al. 2016). Camk2a is selectively expressed in excitatory principal neurons within the 
cortex (Tsien, Chen et al. 1996). The Ribotag mouse harbors an HA-tagged ribosomal protein 
(Rpl22) that is expressed upon crossing with a Cre-recombinase expressing mouse line (Sanz, 
Yang et al. 2009). We crossed the Ribotag mouse with the Camk2a-Cre mouse which results in 
HA-tagged ribosomes specifically in Camk2a+ neurons. The Camk2a-Ribotag mouse then 
allows for the isolation of HA-tagged ribosomes and the associated transcripts specifically from 
a subset of neurons from mouse brain tissue (Hornstein, Torres et al. 2016). This approach is also 
referred to as translating ribosome affinity purification (TRAP) in which purification of tagged 
ribosomes from a specific cell type can be used to obtain profiles of the ribosome bound mRNAs 
(Doyle, Dougherty et al. 2008, Heiman, Schaefer et al. 2008, Dougherty, Schmidt et al. 2010, 
Heiman, Kulicke et al. 2014, Shigeoka, Jung et al. 2018). Since all translated mRNAs are at one 
point associated with ribosomes, we can use the TRAP approach to identify which mRNAs are 
being translated (Kapeli and Yeo 2012). 
We leveraged the Ribotag system to overcome the technical challenges of isolating 
specific cell types from glioma infiltrated brain tissue. We developed a diffusely infiltrating 
glioma mouse model that allows for studying neuron specific alterations. Our glioma model most 
closely resembles human low grade gliomas. We induce glioma growth by injecting mouse 
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glioma cells that have p53 deletion and overexpress PDGFA in Camk2a-Ribotag mice, which 
will be referred to as our Camk2a-Ribotag mouse glioma model. This enables the isolation of 
HA-tagged ribosomes from Camk2a+ neurons from glioma-infiltrated cortex. Using the 
Camk2a-Ribotag mouse glioma model, we found that genes associated with synapses were 
downregulated while genes associated with dendritic spines were upregulated in glioma-
infiltrated cortex compared to normal cortex. The genes associated with synapses included 
synaptophysin, snap25, and synaptotagmin among others. The genes associated with dendritic 
spines are enriched for genes encoding actin-binding proteins that play a role in dendritic spine 
dynamics (Lin and Webb 2009). We further showed an upregulation in the expression of drebrin 
(an actin binding protein expressed in dendritic spines) in the synaptosomal fraction of glioma 
infiltrated cortex. Finally, diolistic imaging revealed a decrease in dendritic spines density in 
Camk2a+ neurons from glioma infiltrated cortex compared to those found in control brains. 
Taken together these findings suggest that there is a degree of reactive plasticity occurring in 
glioma in which the downregulation of synaptic genes and dendritic spines results in the 
upregulation of dendritic spine genes so as to preserve brain function during glioma cell 
infiltration. Our methodology enabled us to identify changes in the translating mRNA profile of 
Camk2a+ neurons in glioma infiltrated cortex and enabled the histological, molecular and 
morphological characterization of Camk2a+ neurons in the brain tumor microenvironment. 
2.2 Results 
Development of diffusely infiltrating glioma mouse model for the isolation of neuron derived 
ribosomes and their associated transcripts 
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Diffuse infiltration of tumor cells into surrounding brain tissue is a major histological 
feature in glioma (Claes, Idema et al. 2007). We developed a glioma mouse model that 
recapitulates the histological features of human glioma (Wesseling, Kros et al. 2011). In our 
model, glioma growth is driven by transformed glial progenitor cells that have p53 deletion and 
overexpress PDGFA resulting in a diffusely infiltrating tumor (figure 2.1a). Transformed glial 
progenitor cells were obtained from a retrovirally induced glioma using methods that have been 
previously established in our lab (Lei, Sonabend et al. 2011, Sonabend, Bansal et al. 2014). 
Retrovirally induced gliomas were initiated by stereotactic injection of PDGFA-IRES-CRE 
retrovirus to the subcortical white matter of p53 floxed neonates (unpublished). These mice also 
harbor a floxed cherry-luciferase reporter allele, upon retroviral delivery glial progenitor cells are 
infected and begin to overexpress PDGFA, have exon 5 of the p53 gene deleted, and express the 
cherry-luciferase reporter allele. The luciferase reporter allows for monitoring tumor growth by 
bioluminescence as demonstrated in other glioma mouse models from our lab (Lei, Sonabend et 
al. 2011, Sonabend, Bansal et al. 2014). We isolated transformed glial progenitor cells from this 
model for stereotactic injection in Camk2a-Ribotag mice. The transformed glial progenitors with 
p53 deletion, PDGFA overexpression, cherry-luciferase reporter expression will be referred to as 
glioma cells in this thesis. We chose to use glioma cells to induce glioma growth rather than the 
retrovirus to induce glioma growth since we were interested in using the Camk2a-Cre mouse to 
induce Cre-recombination in neurons to study neuronal alterations in glioma. I could not have 
used the retrovirus to induce glioma growth in Camk2a-Cre mice because the retrovirus 
(PDGFA-Cre) already expressed Cre-recombinase. The retrovirally induced glioma model is 
currently being characterized by other lab members. Both the glioma cell model and the 
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retroviral model share similar histological and molecular characteristics, which I compared and 
described in chapter 1.  
Glioma cells were injected into Camk2a-Ribotag in adult mice to induce glioma growth. 
These mice develop gliomas that diffusely invade surrounding brain tissue. Histologically, these 
tumors show glioma cells infiltrating the cortex in the right frontal lobe (figure 2.1a). This 
histological feature is referred to as perineuronal satellitosis, which shows neurons often 
surrounded by glioma cells (Claes, Idema et al. 2007). Staining for the pan-neuronal marker 
(NeuN), glial progenitor marker (Olig2) and the proliferation marker (Ki67) showed close 
intermingling of proliferating glioma cells and neurons throughout the cortex (figure 2.1a). The 
Ribotag mouse expresses an HA-tagged ribosomal protein (Rpl22) that is activated upon 
expression of Cre-recombinase in Camk2a+ neurons (Sanz, Yang et al. 2009). This system 
allows for the identification of Camk2a+ neurons by immunohistochemistry and the isolation of 
neuron specific ribosome bound transcripts from glioma brain tissue (figure 2.1a-b). Since tumor 
cells express the luciferase reporter allele, we used this feature to track tumor growth by 
bioluminescent imaging (figure 2.1c). 
We performed immunofluorescence to identify the relative neuron, Camk2a+ neuron, and 
glioma cell populations within the glioma infiltrated cortex. We quantified the number of cells 
expressing NeuN, HA, Olig2, DAPI and the percentage of NeuN positive cells that are HA 
positive from the ipsilateral side of tumor and non-tumor bearing sections. These results showed 
an increase in the number of Olig2 positive cells, indicative of tumor cells, and a decrease in the 
number of neurons (determined by HA and NeuN) which shows that neurons are a minor cell 
population relative to tumor cells within the glioma infiltrated cortex (figure 2.2).  
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Neuron derived ribosome bound transcripts are enriched for neuronal genes in the Camk2a-
Ribotag glioma mouse 
We previously showed that the Camk2-Ribotag mouse can be used to isolate ribosome 
bound transcripts from neurons in normal brain for transcriptional and translational analysis 
(Hornstein, Torres et al. 2016). Our new Camk2a-Ribotag mouse glioma model allowed us to 
isolate neuron specific ribosome bound transcripts from glioma infiltrated cortex for molecular 
analysis. We obtained brain tissue from the right frontal lobe of tumor-bearing mice and non-
tumor bearing mice and performed RNA sequencing on homogenate lysate (total) which includes 
HA-tagged and non-tagged ribosomes and on immunoprecipitated HA-tagged ribosome bound 
transcripts (IP). We calculated the enrichment score (ES) of each gene by dividing normalized 
counts from the IP over the normalized counts from the homogenate (IP/total). By calculating the 
enrichment score of a specific gene we can determine which transcripts were enriched in 
Camk2a+ neurons relative to homogenate brain tissue (Hornstein, Torres et al. 2016). 
We conducted GSEA analysis on the IP from normal and tumor bearing brains to assess 
the enrichment of a set of neuronal genes identified in a previous study (Zhang, Chen et al. 
2014). GSEA analysis showed that both normal brains and tumor brains are enriched for a 
published set of neuronal genes, demonstrating that the isolated transcripts are neuron specific 
(figure2.3a). To verify that neuronal gene enrichment was primarily a contribution from neurons 
rather than glioma cells, we compared the top ranked neuronal genes from the GSEA analysis 
(figure 2.3a) to the highly upregulated tumor cell genes (figure 2.3b). Tumor cell genes were 
defined as the top ranked genes with a positive fold change (calculated from normalized counts 
of homogenate tumor/homogenate normal) which suggests that they are expressed in the 
predominant cell type in the tumor, glioma cells. We calculated the ES for these genes and show 
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that neuronal genes are enriched while tumor cell genes are depleted from the neuron specific 
ribosome bound transcripts. These data show that we can effectively obtain neuron specific 
bound ribosomes from glioma brain tissue in our mouse model. 
Neurons from glioma infiltrated cortex show a downregulation of synaptic genes and an 
upregulation of actin binding transcripts associated with dendritic spines  
We performed gene ontology (GO) analysis using DAVID and identified highly 
significant and enriched GO terms for genes that were downregulated or upregulated based on 
differential gene expression calculated by DESeq. We performed differential gene expression 
between tumor IP and normal IP and considered upregulated genes as those with a log2 fold 
change greater than 0 and downregulated genes as those with a fold change less than 0, the fold 
change was obtained from DESeq output. Based on these criteria, we identified 1110 
downregulated genes with an ES greater than 1.5, these genes were associated with many GO 
terms, including synapse and postsynaptic membrane (figure 2.4a). We identified 304 
upregulated genes with an ES greater than 1.5, several of those genes were associated with actin 
binding and cytoskeleton GO terms (figure 2.4b). The ES to determine downregulated genes was 
obtained from normal brain while the ES to determine upregulated genes was obtained from 
tumor. We performed our analysis this way because if we use the ES from tumor to identify 
downregulated genes then we would not detect all genes that are enriched in neurons since the 
presence of glioma cells among neurons can affect the number of ribosomes per transcript 
thereby affecting the ES derived from tumor. We focused on actin binding genes since these 
were the most highly enriched and upregulated genes determined by GO and because they are 
associated with neuron specific functions. The actin cytoskeleton plays a fundamental role in 
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regulating dendritic spine morphology and ultimately synaptic activity (Lin and Webb 2009, 
Maiti, Manna et al. 2015).  
Actin binding proteins are highly enriched in dendritic spines and some have been shown 
to be transported to dendritic spines via RNA granules for local translation (El Fatimy, 
Davidovic et al. 2016). We queried our differential gene expression analysis for actin binding 
genes enriched in RNA granules and important for dendritic spine dynamics (El Fatimy, 
Davidovic et al. 2016). We identified that several of these dendritic spine genes were upregulated 
and enriched in tumor IP (table 1), we show their p-value and log2 fold change obtained from 
differential expression of tumor IP vs normal brain IP in table 1. Several of these genes were also 
in the list of genes that were enriched in the actin binding GO term. 
To further assess the enrichment of actin binding genes enriched in RNA granules 
important for dendritic spines we performed GSEA analysis to determine the enrichment of 
dendritic spine genes in normal vs tumor brain IP (El Fatimy, Davidovic et al. 2016). We 
obtained a positive and significant GSEA enrichment score for the expression of genes enriched 
in RNA granules (figure 2.4c) which shows that actin binding genes enriched in RNA granules 
and important for dendritic spines are enriched and upregulated in our glioma mouse model.  
We performed the same GSEA analysis to determine the enrichment of actin binding 
genes enriched in RNA granules important for dendritic spines in normal vs tumor brain total 
homogenate. We obtained a negative GSEA enrichment score which shows that actin binding 
genes are not enriched in the total homogenate of glioma brain tissue (figure 2.4d). These results 
show that the enrichment of actin binding genes is only detectable by analyzing genes from 
tumor IP samples not tumor homogenate samples. These results show how neuron specific 
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alterations are undetected when profiling homogenate (bulk) tumor tissue which is likely due to 
1) the low abundance of neurons within the tumor 2) alterations in cellular composition obscure 
cell type specific alterations in bulk tumor 3) the harsh methods used to dissociate glioma brain 
tissue make it difficult to preserve complex neuron morphology. These results provide evidence 
for how the Ribotag system serves as a means to identify an otherwise obscured gene expression 
signature.  
Drebrin, an actin binding protein enriched in dendritic spines, is upregulated in the synaptic 
fraction of glioma infiltrated cortex 
We queried the RNA granule gene list (El Fatimy, Davidovic et al. 2016) for the 
upregulated and enriched actin binding genes in our neuron specific ribosome bound gene 
signature, we identified drebrin, an actin binding gene specific to dendritic spines which had a 
tumor ES of 3.25. We focus on drebrin because it was one of the genes with a high enrichment 
and known function in dendritic spines (Ivanov, Esclapez et al. 2009). We examined whether 
drebrin was also upregulated at the protein level. Given the dendritic spine localization and 
function of drebrin, we decided to biochemically isolate synaptic fractions and test drebrin 
expression there. Synaptic fractions consist of pre and post-synaptic components (synaptosome) 
which are obtained through subcellular fractionation and differential centrifugation (figure 2.5a) 
(Bai and Witzmann 2007, Smalheiser and Lugli 2014). Following synaptosome isolation we 
probed for post-synaptic density protein (PSD95) across the different sub-cellular fractions (total, 
cytosolic, synaptic) in tumor and non-tumor brain lysate. We found PSD95 to be enriched in the 
synaptic fraction (relative to actin loading), suggesting that the synaptosome isolation protocol is 
effectively enriching for post-synaptic proteins (Hunt, Schenker et al. 1996). We also probed for 
HA expression in synaptic fractions and determined that HA expression is enriched in both 
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normal and tumor brain which suggest that HA-tagged ribosomes are localized to the synaptic 
component of dendritic spines and possibly be involved in RNA granule transport for local 
protein synthesis (figure 2.5b).   
Drebrin is an actin binding protein primarily expressed in brain tissue and enriched in 
dendritic spines (Ivanov, Esclapez et al. 2009, Koganezawa, Hanamura et al. 2017). Drebrin was 
one of the highly enriched and upregulated genes in our neuron-specific data, thus we 
investigated the expression of drebrin in the synaptic fraction. We isolated total homogenate and 
synaptic fractions from normal and tumor bearing brains and found a significant increase in 
drebrin expression in the tumor synaptic fraction compared to total homogenate (One way 
ANOVA p=0.0070, p=0.0131 Tukey’s multiple comparison test) (figure 2.5c). Drebrin 
expression in the tumor brain synaptic fraction was also significantly higher compared to normal 
brain synaptic fractions (One way ANOVA p=0.0070, p=0.0333 Tukey’s multiple comparison 
test) (figure 2.5c). Our results are marginally significant, which is likely due to the high degree 
of variability in drebrin expression in tumor synaptic fractions. I suspect that this may be due to 
the heterogeneous cellular composition that is inevitable in glioma brain tissue. The variability in 
drebrin expression as a result of cellular composition may also account for the fact that drebrin, 
although highly enriched in neuron specific ribosome bound transcripts, did not come up in our 
list of differentially expressed genes. The normalized counts for drebrin show that one tumor 
sample is an outlier compared to the other two samples and could have been excluded by the 
algorithm that DESeq uses to calculate differential gene expression analysis, hence the NA p-
value for drebrin. Despite the variability in drebrin expression, our results collectively show that 
in addition to the upregulation of ribosome bound drebrin mRNA, drebrin protein levels are also 
upregulated. These data point to alterations in genes that regulate dendritic spines in the glioma 
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infiltrated cortex and suggest that there may be resulting alterations in dendritic spines in our 
Camk2a-Ribotag glioma model. 
Decreased dendritic spine density in glioma infiltrated cortex suggests that there are alterations 
at the synaptic level 
We hypothesized that the upregulation of actin binding genes involved in dendritic spine 
dynamics would result in alterations in the density and morphology of dendritic spines in glioma 
associated neurons. In order to visualize such changes in situ, we used diolistic labelling in brain 
tissue sections which label neuronal processes with a fluorescent dye (Staffend and Meisel 
2011). Sections were co-stained with the HA antibody to identify Diolistic-labelled Camk2a+ 
neurons (figure 2.6a). Overall, the Camk2a+ neurons within glioma infiltrated cortex 
demonstrated decreased complexity, with fewer dendritic projections and arborizations. We 
determined that Camk2a+ neurons within the glioma infiltrated cortex had significantly fewer 
dendritic spines compared to normal brains (P<0.0001; figure 2.6b). Further analysis of the 
morphology of these dendritic spines will enable a better understanding of dendritic spine 
dynamics in our glioma model. 
The decrease in dendritic spine density and the downregulation of synaptic genes 
identified by ribosome bound mRNA levels suggests that there is decreased synaptic function in 
neurons within the glioma infiltrated cortex. The simultaneous upregulation of actin binding 
genes enriched in dendritic spines suggests that neurons are trying to compensate for the loss of 
dendritic spines and synapses within the glioma infiltrated cortex. This compensatory mechanism 
could explain that the upregulation of dendritic spine genes is induced by the loss of dendritic 
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spines and synaptic genes as a way to compensate for the loss of functional synapses induced by 
infiltrating glioma cells.  
This compensatory mechanism could underlie a form of reactive plasticity that occurs 
during tumor growth in the glioma infiltrated brain. Reactive plasticity occurs in response to 
injury or pathology as a way to preserve neuronal function by reorganization of neural circuits 
(Kong, Gibb et al. 2016). Reactive plasticity has been studied in glioma primarily from a clinical 
perspective, research shows that low grade gliomas that have a slower growth rate allow for a 
higher degree of plasticity, compared to high grade gliomas that generally grow at a faster rate, 
that enables the reorganization of neural circuits in order to preserve cognitive functions (Duffau 
2014). Reactive plasticity could explain our results that show a decrease in dendritic spine 
density and synaptic genes while simultaneously upregulating actin binding genes enriched in 
dendritic spines, however further characterization of the functional consequences of these 
synaptic alterations is needed to provide a better understanding of the neuronal alterations in 
glioma infiltrated cortex. 
2.3 Discussion 
The purpose of our study was to develop a model that allows us to specifically assess neuronal 
alterations from glioma infiltrated brain tissue. We developed the Camk2a-Ribotag mouse 
glioma model to be able to isolate neuron specific ribosome bound mRNAs from the glioma 
infiltrated cortex. Using this mouse model and TRAP methods we identified a decrease in the 
translation of ribosome bound synaptic mRNAs and a decrease in dendritic spine density from 
Camk2a+ neurons. We also identified an upregulation in the translation of ribosome bound actin 
binding mRNAs enriched in dendritic spines and an upregulation of drebrin protein levels in the 
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synaptic fraction of glioma infiltrated cortex. These results suggest that there is a compensatory 
mechanism underlying the neuronal alterations in glioma infiltrated cortex. We propose that this 
compensatory mechanism might underlie a form of reactive plasticity that occurs during glioma 
growth. 
The effects of diffusely infiltrating glioma cells on neurons have been studied in the context of 
glioma associated seizures where it has been shown that glioma cells contribute to neuronal 
hyperexcitability resulting in seizure activity (Takano, Lin et al. 2001, Buckingham, Campbell et 
al. 2011, Campbell, Buckingham et al. 2012, Huberfeld and Vecht 2016). Seizure activity is 
often considered an imbalance of excitatory and inhibitory transmission which can lead to 
alterations in synaptic function (Lepeta, Lourenco et al. 2016). Mouse models of epilepsy have 
shown decreased dendritic spine density that may contribute to impaired synaptic function in 
seizures (Noebels 2015). These findings suggest that the decreased dendritic spine density in our 
glioma model may also induce alterations in synaptic function. In a kainic acid induced rat model 
of epilepsy seizures resulted in a decrease in Snap25, synaptophysin, and Syt1 that correlated 
with impaired cognitive functions (Zhang, Sun et al. 2014). These genes were also 
downregulated in our glioma model and suggest that the downregulation of synaptic proteins 
may be associated with impaired cognitive functions or seizures during glioma growth.  
We discovered that neurons within the brain tumor microenvironment show an upregulation in 
the translation of ribosome bound actin binding mRNAs enriched in dendritic spines. The actin 
cytoskeleton plays an essential role in the formation and dynamics of dendritic spines (Goellner 
2011). Several of these upregulated acting binding mRNAs are highly enriched in neuronal RNA 
granules (figure 2.4b). RNA granules can transport specific mRNAs to distal compartments in 
neurons including dendritic spines for local translation (El Fatimy, Davidovic et al. 2016). The 
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fact that there is an increase in the translation of actin binding mRNAs enriched in RNA granules 
suggests that these mRNAs are being transported in RNA granules for local translation in our 
glioma model. We show that the HA-tag is enriched in normal and tumor brain synaptic fractions 
from synaptosome western blot analysis, which suggest that there are more HA-bound ribosomes 
at or near synapses and that transport via RNA granules for local translation of ribosome bound 
transcripts is a plausible mechanism in our glioma model. This could be addressed using 
ribosome profiling, a method used to measure translation by quantifying the number or 
ribosomes per mRNA and the location of ribosomes on that mRNA (Ingolia, Ghaemmaghami et 
al. 2009). This differs from the TRAP approach used in this chapter since TRAP can only tell us 
whether an mRNA is ribosome bound, not the number of ribosomes per mRNA. Experiments 
using ribosome profiling of synaptic fractions from our glioma model could tell us how 
efficiently actin binding mRNAs are being translated and whether they are being translated or if 
the ribosomes bound to them are stalled.  
We acknowledge that while synaptosome isolation is efficient to enrich for pre and post-
synaptic membrane components, differential centrifugation may also enrich for endoplasmic 
reticulum (ER), mitochondrial or lysosome membranes (Levitan, Mushynski et al. 1972). To 
assess the purity of synaptosomes we blotted for PSD95 which is highly abundant in synaptic 
membranes. We observed an enrichment of PSD95 expression in the synaptic fraction and 
interpreted these results as showing an enrichment for synaptic proteins in the synaptosome 
fraction. We could also blot for markers specific to other subcellular compartments that may get 
enriched in the synaptic fraction. To obtain a more pure synaptosome preparation we could also 
use fluorescent activated cell sorting (FACS) for specific post-synaptic proteins to selectively 
enrich for synaptic membranes (H., A. et al. 2000). 
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We queried the list of RNA granule mRNAs enriched in dendritic spines and our list of neuron 
derived mRNAs and selected drebrin because it is a neuron specific actin binding protein whose 
role in regulating dendritic spines is well established (Ivanov, Esclapez et al. 2009). We 
identified an upregulation of drebrin protein levels in the synaptic fraction of glioma brain tissue 
which shows that one of the actin binding mRNAs is being translated and upregulated at the 
protein level. Overexpression of drebrin in rat neurons was shown to induce long protrusions 
along dendrites, similar to filopodia shaped protrusions which is indicative of immature spines 
(Mizui, Takahashi et al. 2005, Ivanov, Esclapez et al. 2009). Drebrin expression has also been 
shown to regulate synaptic transmission which may contribute to neuronal hyperexcitability in 
seizure models (Sbai, Khrestchatisky et al. 2012, Kreis, Hendricusdottir et al. 2013). These 
studies demonstrate that overexpression of drebrin induces alterations in dendritic morphology 
and neuronal excitability which suggest that the upregulation in drebrin expression in our glioma 
model may contribute to immature spine formation and neuronal hyperexcitability. Future 
experiments that assess neuronal excitability by electrophysiological recordings could address 
our hypothesis, experiments that assess dendritic spine morphology to identify immature and 
mature spines would also be able to assess dendritic spine alterations in our glioma model. 
 We discovered a decrease in the number of dendritic spines per length of dendritic segment in 
Camk2a+ neurons which suggests that there is a decrease in excitatory synapses that could result 
in impaired synaptic function in glioma brain tissue. We found one study that identified 
decreased dendritic spine density in human glioma (Špaček and Hartmann 1983) while a more 
recent study identified alterations in dendritic morphology and disrupted cortical structure in the 
peritumoral region in human astrocytomas (Goel, Wharton et al. 2003). Decreased dendritic 
spine density has been observed in other neurological disorders including epilepsy and focal 
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cortical dysplasia which are associated with impaired synaptic function (Lin and Webb 2009, 
Herms and Dorostkar 2016). The alterations in dendritic spine density seen in our glioma model 
suggest that there is impaired synaptic function which we suggest may contribute to the cognitive 
deficits observed in glioma.  
We propose that the decrease in dendritic spines and translation of synaptic mRNAs results in a 
compensatory mechanism that increases the translation of actin binding mRNAs as an attempt to 
compensate for the loss of synaptic function. This type of compensatory mechanism could 
explain a form of reactive plasticity that occurs during low grade glioma growth. Reactive 
plasticity is thought of as the reorganization of synapses in response to injury or pathology as a 
way to preserve neuronal function (Nudo 2013, Kong, Gibb et al. 2016). During low grade 
glioma growth glioma cells diffusely invade a large amount of surrounding brain tissue before 
any neurological impairment can be detected. It has been suggested that the slow growing nature 
of low grade gliomas enables reactive plasticity to occur. Reactive plasticity occurs more often in 
low grade gliomas which are slow growing tumors rather than in high grade gliomas which grow 
faster, the high degree of reactive plasticity in low grade glioma is attributed to the longer time 
frame (years) available for the reorganization of neural circuits (Desmurget, Bonnetblanc et al. 
2007). The high degree of reactive plasticity in low grade glioma has also been show in contrast 
to reactive plasticity in acute brain injuries such as stroke which have a rapid onset (minutes) and 
frequently result in detrimental neurological impairment (Desmurget, Bonnetblanc et al. 2007, 
Kong, Gibb et al. 2016). The mechanisms underlying reactive plasticity after brain injury are 
currently being investigated (Nudo 2013) and motivate future research to identify the molecular 
mechanisms underlying reactive plasticity in glioma.  
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The work described in Chapter 2 of this thesis shows the development of the Camk2a-Ribotag 
mouse glioma model and how we used TRAP methodology to identify translational alterations 
from neurons in glioma infiltrated cortex. The neuronal alterations we identified point to 
impaired synaptic function which motivates future studies to assess the consequences of these 
alterations on neuronal synapses in glioma. Ultimately the evaluation of this and future studies 
that focus on characterizing neuronal alterations in the brain tumor microenvironment will 




































Figure 2.1: Diffusely infiltrating Camk2a-Ribotag mouse glioma model. A, 
Stereotactic injection of PDGFA/p53 deleted/mCherry-luciferase expressing cells in 
subcortical white mater of  Camk2a-Ribotag mice result in diffusely infiltrating glioma 
with features of human glioma such as perineuronal satellitosis. B, In the Ribotag system 
the Ribotag mouse is crossed to a Camk2a-Cre mouse resulting in Camk2a-Ribotag mice 
in which Camk2a+ neurons express the HA-tag. Immunofluorescence shows neurons 
(HA+) and tumor cells (olig2+) intermingled in mouse tumor cortex. C, Bioluminescent 
images show the presence of a tumor at 14 days post glioma cell injection (dpi) and 












































Figure 2.2. Immunofluorescent stain quantification from normal and Camk2a-
Ribotag glioma infiltrated cortex. A) Average number of cells was determined from 3 
adjacent fields per brain section for 3 normal brains and 3 tumor brains. Error bars show 
standard error. Dapi p=0.0235, NeuN p=0.0043, HA p=0.0002, Olig2 p=0.0091. B) Percent 
of HA+ cells relative to NeuN+ cells in normal and tumor brain. Average percentages were 


































































Figure 2.3: Enrichment of neuronal genes in Camk2a-Ribotag tumor IP. A, GSEA 
enrichment of neuronal genes in normal and tumor brain IP. B, Heatmap of highly 
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Actin binding GO: 0003779 20 4.32 2.1E-7 
Cytoskeleton GO: 0005856 26 1.72 9.1E-3 
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Synapse GO:0045202 75 3.49 7.1E-17 
Postsynaptic membrane GO:0045211 83 2.94 8.3E-8 
Protein transport GO: 0015031 58 1.95 1.9E-6 
C 
Figure 2.4: Camk2a+ neurons from glioma infiltrated cortex have alterations in 
synaptic and dendritic spine genes. A, Gene ontology terms for genes upregulated in 
tumor IP B) Gene ontology terms for downregulated genes in tumor IP. C) GSEA 
enrichment for dendritic spine genes in tumor vs. normal brain IP (Ribotag). D) GSEA 










gene ES (tumor 
IP/tumor input) 
Log2 fold change 
(tumor IP vs 
normal IP) 
p-value 
MYH10 4.04 1.12 1.43E-04 
LIMCH1 3.97 1.52 5.48E-15 
MYH9 3.72 2.70 5.30E-147 
SPTBN1 3.26 0.93 3.48E-04 
DBN1 3.25 0.89 NA 
DST 2.99 1.30 8.71E-37 
MYH14 2.74 1.59 5.16E-33 
SPTAN1 2.53 1.03 4.29E-05 
MYO5A 2.46 0.99 3.04E-09 
SYNE2 2.44 1.71 1.35E-61 
MPRIP 2.29 0.29 1.07E-03 
TES 2.07 1.47 1.48E-08 
MICAL1 1.98 3.01 2.34E-89 
MYO6 1.84 0.60 4.46E-04 
SVIL 1.58 2.83 2.50E-131 
GSN 1.52 1.32 4.29E-24 
 
Table 1. Actin binding genes enriched in dendritic spines and upregulated in Camk2a+ 
neurons from glioma infiltrated cortex. Table shows actin binding genes enriched in RNA 
granules and important for dendritic spine dynamics, ES was obtained from the ratio of 
normalized counts in tumor IP/normal brain IP., log2 fold change and p-value were obtained 



































Figure 2.5: Dendritic spine gene drebrin has increased levels in Camk2a+ neurons. 
A, Total, cytosolic, and synaptic fractions were isolated from right frontal lobe in normal 
and tumor brains of 16 week old mice, PSD95 is a post-synaptic marker, actin was used 
as a loading control. B, HA expression of tumor and normal brain total (T) and 
synaptosome (S) fractions, 2 normal and 2 tumor brains were used. C, Drebrin expression 
in total and synaptic fractions in normal and tumor brains. D, Quantification of drebrin 
expression from 5 different normal brains and 5 different tumor brains. Drebrin signal 
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Figure 2.6: Decrease in dendritic spine number in Camk2a+ neurons in glioma 
infiltrated cortex. A, Camk2a+ neurons in glioma infiltrated cortex are identified by HA 
staining (magenta) from control (top) and tumor (bottom) Camk2a-Ribotag tumors.. 
DAPI (blue), Olig2 (green), DiI (red) and HA (magenta), (Bars,50 μm). The images at the 
right are magnifications of the insets which show the number of dendritic spines (Bars, 10 
μm). B, quantitation of the number of dendritic spines per 10 μm of dendrite length in 








mTOR inhibition with AZD induces transcriptional and translational 
alterations in the Camk2a-Ribotag mouse glioma model 
 
3.1 Introduction 
mTOR signaling  has the ability to regulate cell survival, growth, and proliferation in 
many cell types (Laplante and Sabatini 2009). In addition, mTOR regulates neuron specific 
functions such as neuronal excitability and synaptic plasticity (Bockaert and Marin 2015). 
mTOR regulates these processes in response to growth factors, amino acids, neurotransmitters, 
and neural activity (Takei and Nawa 2014). mTOR has been shown to regulate translation 
initiation through 4EBP and cell growth and size through S6K. mTOR activation results in the 
phosphorylation S6K1 and 4EBP1 (Guertin and Sabatini 2009), the former has been associated 
with synaptic plasticity (Bockaert and Marin 2015).  
Alterations in mTOR signaling have been implicated in many neurological diseases 
(Hoeffer and Klann 2010, Wong 2013). Dysregulation of the mTOR pathway generally results in 
the upregulation of mTOR activity that is seen tuberous sclerosis complex disease (TSC), focal 
cortical dysplasia, and epilepsy (Lipton and Sahin 2014, Citraro, Leo et al. 2016). Upregulated 
mTOR activity results in enlarged neurons and abnormal cortical organization which is thought 
to contribute to the pathology of some neurological diseases. Several mouse studies have shown 
that seizures resulting from dysregulated mTOR activity can be prevented and inhibited with the 
mTOR inhibitor rapamycin, suggesting the potential use of mTOR inhibitors for seizures in other 
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neurological disorders (Meikle, Talos et al. 2007, Zeng, Xu et al. 2008) (Huang, Zhang et al. 
2010, Guo, Zeng et al. 2013). Due to the neurological symptoms associated with glioma and the 
dysregulation of mTOR that contributes to neurological disease, we hypothesize that mTOR 
signaling is involved in regulating neuronal alterations in glioma infiltrated cortex in our 
Camk2a-Ribotag mouse glioma model. 
To identify neuron specific ribosome bound transcripts from our Camk2a-Ribotag mouse 
glioma model we used translating ribosome affinity purification (TRAP) which has been 
previously described (Doyle, Dougherty et al. 2008, Heiman, Schaefer et al. 2008). Applying 
TRAP methods we immunoprecipitated HA-tagged ribosomes from tumor brain tissue, isolate 
the associated mRNAs and identify them by RNA sequencing. All translated mRNAs are at one 
point associated with ribosomes, which allows us to use the TRAP approach to determine which 
transcripts are being translated (Kapeli and Yeo 2012). Using this approach we identified 
alterations in the translation of ribosome bound mRNAs in response to mTOR inhibition with the 
ATP competitive mTOR inhibitor AZD8055 (AZD). Additionally, we extracted mRNAs from 
homogenate brain tumor tissue, which includes ribosome bound and non-ribosome bound 
mRNAs, and refer to any alterations identified from this analysis as transcriptional alterations.  
In this chapter I describe how treating Camk2a-Ribotag glioma mice with AZD for 6 
hours can reverse some of the transcriptional alterations in cell type specific mRNAs including 
those for glioma cells and neurons. We also show that mTOR inhibition reversed the neuron 
specific translational alterations after a 6 hour treatment with AZD. AZD treatment resulted in 
the upregulation of many neuron specific mRNAs including genes associated with synapses. We 
also determined that AZD treatment downregulated the translation of actin binding genes 
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enriched in dendritic spines. Overall, these data suggest that mTOR can regulate several of the 
transcriptional and translational alterations of many cell type specific genes in our glioma model.  
3.2 Results 
AZD8055 inhibits mTOR signaling in normal mouse brain tissue 
The effects of delivering AZD in vivo have been shown to be safe and effective in a 
different mouse glioma model (Chresta, Davies et al. 2010). We decided to characterize the 
effects of AZD in vivo to validate these findings. We treated non-tumor bearing mice with AZD 
(20mg/kg) and sacrificed mice 1 and 8 hours after a single treatment. We also delivered a second 
dose of AZD (20mg/kg) after 24 hours in one mouse and sacrificed 1 hour after the second dose 
(25 hours, figure 3.1a). mTOR activation results in the phosphorylation S6K1 and 4EBP1. 
Activated S6K1 phosphorylates ribosomal protein S6 (pS6) which can regulate the translation of 
TOP mRNAs (Guertin and Sabatini 2009). 4EBP inhibits translation, upon mTOR activation 
4EBP is phosphorylated (p4EBP1) and the inhibitory effect of 4EBP1on translation is reduced. 
Non-phosphorylated 4EBP is often increased as translation in inhibited via mTOR inhibition 
(Moschetta, Reale et al. 2014). We observed a marked decrease in pS6 and p4EBP expression 
after 1 hour AZD treatment (figure 3.1a). There also appears to be an increase in non-
phosphorylated 4EBP after 1 hour treatment, suggesting that there is inhibition of translation 
(figure 3.1a). The effects of AZD on pS6 appear to be transient, since after 8 hours of AZD 
treatment pS6 levels returned to basal non-treated levels (figure 3.1a). A second dose of AZD 24 
hours after the first dose inhibited pS6 levels as was seen 1 hour after the first dose suggesting 
that AZD has transient effects on pS6 and p4EBP expression (figure 3.1a). The transient effects 
of AZD on mTOR targets can be attributed to the short half-life of AZD (few hours), despite the 
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kinetics of AZD continued doses have shown to have long term effects on mTOR regulated 
processes (Chresta, Davies et al. 2010, Naing, Aghajanian et al. 2012, Rosborough, Raïch-Regué 
et al. 2014). To test if the transient effects of AZD are dose dependent we performed a dose-
response study in vivo. 
We treated non-tumor bearing mice with AZD and sacrificed mice 1, 2, 4, 6, 8, 16, 24 
hours after AZD treatment. We used 20mg/kg AZD and 100mg/kg AZD to see if the effects of 
mTOR inhibition were dose dependent. We observed a marked decrease in pS6 levels after 1 
hour of AZD (20mg/kg) treatment and a subsequent increase in pS6 expression back to control 
levels after 2 hours of treatment (figure 3.1b). Using a higher dose of AZD (100mg/kg) we saw a 
sustained decrease in pS6 levels up to 6 hours after treatment (figure 3.1b). These results suggest 
that the effects of AZD are prolonged (up to 6 hours) with a higher dose in vivo. We did not 
observe any side effects as a result of oral gavage administration of 20mg/kg or 100mg/kg AZD 
within 24 hours of treatment. Based on these findings we chose to use 6 hours of 100 mg/kg for 
our experiments in vivo. 
AZD8055 alters the transcription of some cell type specific genes in our Camk2a-Ribotag mouse 
glioma model 
We assessed mTOR activity in our Camk2a-Ribotag mouse glioma model and observed 
pS6 expression throughout glioma infiltrated cortex (figure 3.2). Although we did not quantify or 
perform double stainining to determine cell type specificity of mTOR activity, we show that 
there is mTOR activation in neurons (determined by morphology) in glioma infiltrated cortex 
(figure 3.2). We treated mice with 100 mg/kg AZD and sacrificed them 6 hours after treatment. 
Our immunohistochemistry results show that mTOR activity is decreased after 6 hour AZD 
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treatment throughout glioma infiltrated cortex and appears to be decreased in neurons in both the 
ipsilateral and contralateral cortex (figure 3.2).  
To determine the effects of mTOR inhibition with AZD treatment we performed RNA 
sequencing on treated and non-treated tumor brains. We obtained differential gene expression 
analysis in homogenate tumor vs normal brain. Homogenate brain lysate contains ribosome 
bound and non-ribosome bound mRNAs (figure 3.4a) which means that by assessing 
homogenate tissue mRNA levels from we can only determine the total abundance of transcripts, 
not whether they are being translated, and thus the alterations identified from homogenate brain 
tissue are referred to as transcriptional. Differential gene expression analysis identified 6054 
differentially expressed genes in tumor brains (p-value <0.05). Highly upregulated genes in the 
tumor (log2foldchange>0) have been shown to be expressed in many glioma cells from 
retrovirally induced glioma models (Assanah, Lochhead et al. 2006).  These genes are likely 
among the most upregulated genes because glioma cells compose the majority of cells in brain 
tumor tissue, thus marked transcriptional alterations in these cells will conceal alterations in 
minor cell populations in brain tumor tissue, an issue we address in chapter 2 of this thesis. We 
plotted differential gene expression output measures (adjusted p-value and log2foldchange) and 
show that Ki67, Olig2 and PDGFRa are among the most highly differentially expressed genes in 
our glioma model (figure 3.3a) which shows that there is an increase in the transcription of 
glioma cell mRNAs in brain tumor homogenate. 
We performed RNA sequencing of treated tumor homogenate treated with AZD for 6 
hours. We performed differential gene expression analysis between treated tumor and untreated 
tumor homogenate. We plotted differential gene expression output measures (adjusted p-value 
and log2foldchange) and show that Olig2 and PDGFRa are downregulated after mTOR 
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inhibition with AZD (figure 3.3b) which shows there is a decrease in the transcription of glioma 
cell mRNAs in brain tumor homogenate. We used Panther to determine the GOs that 
differentially expressed genes are associated with. We identified 1601 differentially expressed 
genes (p-value<0.05) that were upregulated after mTOR inhibition (log2 fold change>0), these 
genes were associated with ion transport GO terms (figure 3.4b). These genes included several 
excitatory ion channel genes which show that mTOR inhibition in our glioma model results in an 
upregulation of the transcription of excitatory ion channel mRNAs.  
There were 1573 differentially expressed genes (p-value<0.05) that were downregulated 
after mTOR inhibition with AZD (log2 fold change<0) and associated with transcription and 
DNA replication GO terms (figure 3.4c). mTOR has been shown to regulate several genes 
associated with transcription which suggests that mTOR inhibition will result in alterations of 
transcriptional regulation (Mayer and Grummt 2006). Our results that mTOR inhibition induces 
a decrease in mRNAs associated with transcriptional activity which suggests that mTOR 
regulates transcription in our glioma model. 
The fact that mTOR inhibition with AZD transcriptionally downregulated tumor cell 
mRNAs suggested that mTOR inhibition affects mRNAs specific to other brain cell types. This 
finding motivated us to assess the transcription of cell type specific mRNAs from neurons and 
OPCs since glioma cells in our tumor model are mainly OPCs. To do this we used published 
mRNA cell type specific expression profiles (Zhang, Chen et al. 2014). We queried the top 500 
cell type specific genes for neurons and OPCs and compared each list to our list of significantly 
upregulated and downregulated genes after AZD treatment and show a heatmap of normalized 
counts in normal, tumor and AZD treated tumor brains (figure 3.5). From the top 500 neuron 
specific genes we identified 70 genes were upregulated after AZD and 11 were downregulated 
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after AZD. From the top 500 OPC specific genes we identified 11 genes were upregulated after 
AZD and 144 were downregulated after AZD.  
We show that mTOR inhibition with AZD reversed many of the transcriptional 
alterations in tumor tissue. Some of the neuron specific genes that were downregulated in tumor 
homogenate were upregulated after mTOR inhibition (figure 3.5). Our data also show that many 
OPC specific genes which are also expressed in glioma cells that were upregulated in tumor 
tissue were downregulated after mTOR inhibition. These results show the effects of mTOR 
inhibition on the transcription of some cell type specific mRNAs in homogenate glioma tissue, 
and suggest that mTOR inhibition with AZD treatment for 6 hours reverses many of the cell type 
specific transcriptional alterations induced by diffusely infiltrating glioma cells.  
We can attribute many of the transcriptional alterations in non-treated tumor to the 
changes in cellular composition that have occurred at this late stage of tumor growth. The glioma 
tissue samples used for RNA sequencing were obtained from a late stage in tumor growth when 
there is a large diffusely infiltrating tumor present. As I describe in Chapter 2 of this thesis, 
cellular composition at this stage of tumor growth is altered, brain tissue is mainly composed of 
glioma cells and there are fewer neurons within this tissue. Based on these results we can 
attribute the transcriptional downregulation of many neuron specific mRNAs to the low density 
of neurons in homogenate tumor tissue, while the upregulation of OPC specific mRNAs is likely 
a result of a high density of glioma cells present in homogenate tumor tissue.  
We believe that the marked effects of mTOR inhibition on cell type specific mRNAs is 
not due to changes in cellular composition, since mTOR inhibition only lasted for 6 hours. We 
hypothesize that the marked effects of mTOR inhibition on cell type specific mRNAs precede 
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the translational effects of mTOR inhibition in brain tissue. To assess the translational effects of 
mTOR inhibition in neurons, we used TRAP methods to identify neuron specific ribosome 
bound mRNAs in our glioma mouse model.   
AZD8055 alters the translation of neuron specific mRNAs in our glioma mouse model 
To identify the effects of mTOR inhibition with AZD we used TRAP to identify neuron 
specific ribosome bound mRNAs. We immunoprecipitated HA-tagged ribosome bound 
transcripts (IP) from tumor brains treated with AZD for 6 hours and performed RNA sequencing. 
We performed differential gene expression analysis (DESeq) on IP treated tumor vs IP tumor. 
We obtained the enrichment score (ES) from the ratio of treated tumor IP counts (determined 
from TRAP) over treated tumor homogenate counts (determined from RNA seq of homogenate) 
and refer to this as the treated ES. From our differential gene expression analysis we searched 
among significantly expressed genes (p value<0.05) and found 738 genes that were upregulated 
(log2fold change>0) and had an ES>1.5 (figure 3.6b). Gene ontology analysis revealed that these 
genes are associated with synaptic GO terms (figure 3.6b). Synaptic GO terms included genes 
such as Syt1, snap25 and synaptophysin. These genes are associated with synaptic vesicle 
exocytosis suggesting that mTOR inhibition with AZD treatment upregulated the translation of 
these mRNAs in our glioma model. These synaptic mRNAs were translationally decreased in 
tumor brains which suggest that a 6 hour treatment with AZD reverses the translational 
alterations observed in tumor brains.  
We performed gene ontology analysis for genes that were downregulated after mTOR 
inhibition with AZD. From our differential gene expression analysis we searched among 
significantly expressed genes (p value<0.05) that were downregulated (log2fold change<0) and 
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had an ES>1.5 and identified 163 genes (figure 3.6c). We used the ES from tumor brains to 
determine genes enriched in neurons from tumor brains and downregulated by AZD treatment. 
Gene ontology analysis revealed that these genes are associated with actin binding GO terms 
(figure 3.6b). These GO terms include several actin binding genes enriched in dendritic spines 
such as mical1, drebrin, limch1. These results show that mTOR inhibition with AZD 
downregulated the translation of actin binding genes enriched in dendritic spines suggesting that 
mTOR can regulate the translation of these mRNAs. Several of the actin binding mRNAs were 
translationally upregulated in non-treated tumors (Chapter 2) which suggests that mTOR 
inhibition with AZD for 6 hours reversed these translational alterations.   
To visualize the magnitude of the translational alterations induced by mTOR inhibition 
we queried genes that were significantly upregulated in AZD treated tumor IP (p<0.05), 
log2foldchange>0) and enriched in AZD treated tumor IP (ES>1.5) which resulted in a list of 
738 genes (figure 3.7a). From the list of 738 genes, we generated a heatmap that shows the 
normalized counts from normal, tumor and AZD treated IP of upregulated genes in AZD treated 
tumor IP (figure 3.7b). Our data show that these genes were downregulated in tumor IP, 
interestingly several of these genes are synaptic proteins which suggests that mTOR inhibition 
reversed the translational alterations of synaptic proteins. Similarly we queried genes that were 
significantly downregulated in AZD treated tumor IP (p<0.05), log2foldchange>0) and enriched 
in tumor IP (ES>1.5) which resulted in a list of 163 genes (figure 3.7c). From the list of 163 
genes, we generated a heatmap that shows the normalized counts from normal, tumor and AZD 
treated IP of downregulated genes in AZD treated tumor IP (figure 3.7d). Our data show that 
actin binding genes were upregulated in tumor IP, several of these genes included actin binding 
genes and conversely several neuron specific mRNAs that are translationally downregulated in 
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tumor brains are upregulated by AZD treatment (synaptic mRNAs). These results highlight how 
mTOR inhibition with AZD for 6 hours can reverse several of the neuron specific translational 
alterations in our glioma model.   
3.3 Discussion 
In this chapter we demonstrated that mTOR activity is detectable in brain tissue and can 
be inhibited by the mTOR inhibitor AZD. We show that mTOR inhibition with AZD for 6 hours 
results in transcriptional alterations in many cell type specific transcripts as determined by 
mRNA levels in homogenate AZD treated tumor tissue. We also show that mTOR inhibition 
with AZD results in translational alterations in several neuron specific transcripts as determined 
by TRAP profiling of neuron specific ribosome bound mRNAs. Our findings suggest that mTOR 
signaling regulates the translation of several neuron specific transcripts as evidenced by the 
reversal of these alterations after a 6 hour treatment with AZD and motivate future studies to 
assess the effects mTOR inhibition with AZD on synaptic function.   
We showed that delivering AZD by oral gavage crosses the blood brain barrier and 
inhibits mTOR activity. mTOR inhibition with AZD occurred 1 hour after administration which 
shows that the effects of AZD occur shortly after drug administration. We also show that AZD 
transiently inhibits mTOR activity as demonstrated by pS6 returning to basal levels 8 hours after 
treatment. The transient effects of AZD have been reported, despite this, these studies have 
shown that daily AZD treatment induced robust effects on cell proliferation and tumor growth 
(Chresta, Davies et al. 2010, Rosborough, Raïch-Regué et al. 2014). These studies suggest that 
despite the short half-life of AZD, daily mTOR inhibition with AZD is able to induce changes in 
cell function. In our experiments, we used a 6 hour treatment with AZD to assess the immediate 
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effects of mTOR inhibition on transcriptional and translational alterations, however daily 
treatment with AZD might be required to observe changes in cell function in brain tissue.  
We show that mTOR activity is detectable in glioma infiltrated cortex and point out the 
expression of pS6 in neurons. We show that a 6 hour treatment with AZD inhibits mTOR 
activity in glioma infiltrated cortex and that neurons are particularly sensitive to mTOR 
inhibition. We assessed the effects of mTOR inhibition with AZD on the transcription of 
mRNAs from homogenate tumor tissue. These results showed that AZD reversed several of the 
cell type specific transcriptional alterations induced by diffusely infiltrating glioma cells, such as 
the downregulation of glioma cell genes PDGFRa and Olig2 after AZD treatment. Using 
published gene cell type specific expression profile data we show that several neuron specific 
mRNAs that were downregulated in homogenate tumor tissue were upregulated after AZD 
treatment. The reversal of these transcriptional alterations after only 6 hours of mTOR inhibition 
with AZD suggest that these effects are mediated by mTOR inhibition rather than by changes in 
cellular composition.  
To identify the effects of mTOR inhibition with AZD on the translation of neuron 
specific ribosome bound mRNAs we used TRAP methods to isolate neuron specific transcripts. 
mTOR inhibition with AZD induced an upregulation in the translation of neuron specific 
mRNAs that were associated with synaptic genes including Snap25, synaptophysin and Syt1. 
These synaptic genes were translationally downregulated in tumor brains, which suggests that 
their upregulation after AZD treatment is an attempt to restore synaptic function. mTOR 
inhibition with AZD also induced a downregulation in the translation of neuron specific mRNAs 
that were associated with actin binding genes enriched in dendritic spines. These genes included 
mical1, drebrin, and limch1 among others. Several of the translationally downregulated actin 
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binding genes after AZD treatment were among those that were translationally upregulated in 
tumor brains. These results show that AZD reversed the translational alterations identified in 
tumor brains and suggest that the translation of actin binding genes enriched in dendritic spines 
is regulated by mTOR signaling in our glioma model. mTOR signaling has been associated with 
regulating dendritic spine morphology and synaptic plasticity (Hoeffer and Klann 2010). 
Increased mTOR activation resulted in increased dendritic spine density in a mouse model of 
autism (Tang, Gudsnuk et al. 2014) while mTOR inhibition resulted in decreased dendrite 
branching and arborization (Jaworski, Spangler et al. 2005). Future experiments that assess the 
effects of mTOR inhibition with AZD on dendritic spine dynamics would be informative to 
understand how mTOR inhibition affects dendritic spine alterations in our glioma model.  
The work described in this chapter shows that mTOR inhibition with a 6 hour AZD 
treatment is achieved in normal and tumor brains. We show that AZD induced alterations in the 
transcription of several cell type specific mRNAs found in homogenate lysate. Lastly, we 
demonstrate that AZD induced alterations in the translation of several neuron specific ribosome 
bound mRNAs including the upregulation of synaptic genes and downregulation of dendritic 
spine genes. These findings suggest that mTOR inhibitors can reverse neuronal alterations at the 
level of translation which might contribute to prevent some of the neuronal alterations associated 
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Figure 3.1: mTOR activity in response to AZD in normal mouse brains. A, normal 
mice were treated with AZD (20mg/kg by oral gavage) once and sacrificed 1 and 8 hours 
after treatment for western blot analysis of the right frontal brain lobe. The mouse treated 
with AZD for 25 hours was treated twice (once at time 0 and 1 hour before sacrificing). B, 
normal mice were treated with 20 mg/kg and 100 mg/kg AZD for the time specified. Brain 
tissue from 0 hours was collected from untreated mice.  






































Figure 3.2: pS6 immunostaining in vehicle and AZD treated glioma mouse brain. Top 
row shows a 4x image of vehicle and AZD treated brain sections (AZD 100 mg/kg). Red 
square show ipsilateral tumor cortex, blue square show contralateral cortex. Second rows 
show 40x image of ipsilateral glioma infiltrated cortex, black arrows point to what is 
morphologically characterized as a neuron, bottom right corner shows one neuron as an 
example. Third row shows a 40x image of contralateral non-infiltrated cortex, black arrows 
point to neurons in non-infiltrated cortex. mTOR inhibition with AZD shoes decreased 
mTOR activity in neurons from both ipsilateral and contralateral cortex, black arrows point 














































Figure 3.3: mTOR inhibition with AZD targets glioma cell genes in our glioma mouse 
model.  A, Plot of all differentially upregulated (log2 fold change>0) and downregulated 
(log2 fold change<0) genes in tumor homogenate RNA sequencing data compared to 
normal brain. Genes labeled in pink include those expressed in OPCs (Olig1, Olig2, 
PDGFRa, Cspg4) and a proliferation marker (Ki67), among the most significantly 
expressed genes.  B, Plot of differentially upregulated and downregulated genes in tumor 
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Transport GO: 0006810 158 1.49 2.2E-7 
Ion transport GO:0006811 62 1.82 6.3E-6 
Mitochondrial outer membrane GO:0005741 19 2.12 3.8E-3 
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Transcription, DNA templated GO:0006351 224 1.62 7.2E-14 
DNA binding GO:0003677 217 1.62  
Regulation of transcription, DNA-templated 










Figure 3.4:  Gene ontologies for homogenate mRNAs affected by mTOR inhibition 
with AZD in our glioma mouse model.  A, Homogenate mRNAs include those with HA 
tagged (blue) ribosomes, non HA-tagged ribosomes (white). B, Gene ontology terms of 
significantly (p<0.05) upregulated genes (1601 genes) in tumor homogenate from AZD 
treated brains . Upregulated genes were determined as having a log2 fold change (FC) 
greater than 0. C, Gene ontology terms of significantly (p<0.05) downregulated genes 
(1573 genes) in tumor homogenate from AZD treated brains. Downregulated genes had a 
FC less than 0. FC and p-values were obtained from differential gene expression analysis 
with DESeq2. Gene ontology terms for the most enriched gene clusters are shown, these 
were identified using DAVID gene ontology analysis. 
 





















































Figure 3.5: Neuron and OPC specific genes from homogenate affected by mTOR 
inhibition with AZD in our glioma mouse model.  Heatmaps of normalized counts for cell 
type specific genes (obtained from Zhang et al 2014) for neuron and OPC specific genes. 
The first 3 columns are normalized counts for normal brain, the next 3 are tumor brain, and 
the last 3 are AZD treated tumor brains.  Top 500 genes from Zhang et al 2014 were queried 
for significantly expressed genes in AZD treated tumor homogenate. Up after AZD refers to 
significantly upregulated genes (dashed line), and Down after AZD refers to significantly 
downregulated genes (solid line). Up regulation was determined by a positive log2 fold 
change and downregulation was determined by a negative log2 fold change from differential 
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Synapse GO:0045202 47 2.87 2.9E-10 
Cell junction GO:0030054 49 2.10 1.8E-6 
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Actin binding GO: 0003779 19 7.21 1.3-10 
Actin cytoskeleton GO:0015629 10 6.61 2.1E-5 
Cytoskeleton GO: 0005856 20 2.39 6.5E-4 
Figure 3.6: Gene ontologies for Camk2a+ HA-tagged mRNAs affected by mTOR 
inhibition with AZD in our glioma mouse model. A, HA-tagged ribosomes and their 
associated mRNAs. B, Gene ontology terms of significantly (p<0.05) upregulated and 
enriched (ES>1.5) genes in tumor IP from AZD treated brains (738 genes). Upregulated 
genes were determined as having a log2 fold change (FC) greater than 0. C, Gene 
ontology terms of significantly (p<0.05) downregulated and enriched (ES>1.5) genes in 
tumor IP from AZD treated brains (163 genes). Downregulated genes had a FC less than 
0. FC and p-values were obtained from differential gene expression analysis with 
DESeq2. ES from treated tumor brains was used to identify enriched genes that were 
upregulated, ES for non-treated tumor brains was used to identify enriched genes that 
were downregulated. Gene ontology terms for the most enriched gene cluster are shown, 

































Figure 3.7: mTOR inhibition with AZD reverses some of the translational alterations 
in neuron specific genes. A) Venn diagram of genes that were upregulated in AZD treated 
tumor IP (blue) and genes that were enriched in treated tumor IP (pink), the 738 genes that 
are upregulated and enriched in AZD treated tumor IP are shown in panel B.  B) 
Normalized counts for genes that were upregulated in AZD treated tumor IP and enriched 
in AZD treated IP. C) Venn diagram of genes that were downregulated in AZD treated 
tumor IP (blue) and genes that were enriched in tumor IP (pink), the 163 genes that are 
downregulated in AZD treated tumor IP and enriched in tumor IP are shown in panel D. D) 
Normalized counts for genes that were downregulated in AZD treated tumor IP and 
enriched in tumor IP. Upregulated (log2foldchange>0) and downregulated genes 
(log2foldchange<0) were determined from differential gene expression with DESeq2. ES 
from treated tumor brains was used to identify enriched genes that were upregulated, ES for 
non-treated tumor brains was used to identify enriched genes that were downregulated. 
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Ribosome profiling reveals translational alterations in the Camk2a-Ribotag 
mouse glioma model 
 
4.1 Introduction 
Regulating the translation of mRNA into protein is essential for cells to modulate gene 
expression in response to endogenous and exogenous signals. Translational regulation is critical 
for maintaining a homeostatic balance during cell processes such as cell growth, proliferation 
and development. Protein synthesis is an energetically costly process for cells and is therefore 
under tight regulation (Hershey, Sonenberg et al. 2012). Translational regulation has been shown 
to play a critical role during pathological and non-pathological conditions thus identifying the 
mechanisms underlying translational control are needed for understanding regulation of gene 
expression in normal and disease conditions (Sonenberg and Hinnebusch 2009).  
Dysregulation of translation occurs in cancer since some of the same pathways that 
contribute to cancer cell growth and proliferation also regulate translation. This is supported by 
the increased number of ribosomes and increased expression of components of the translational 
machinery seen in cancer (Silvera, Formenti et al. 2010). Recent analysis of translation 
regulation in tumor cells in one of our retrovirally induced mouse glioma models showed that 
tumor cells have lower translational efficiencies relative to other cell types in glioma, suggesting 
that there is a cell type specific mechanism of translational regulation in glioma (Gonzalez, Sims 
et al. 2014). 
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To study translation, ribosome profiling has emerged as a method to measure the 
translation efficiency per gene and has also been shown to be more correlated with protein 
synthesis compared to RNA sequencing (Maier, Güell et al. 2009, Ingolia 2016). Ribosome 
profiling tells us the number of ribosomes (ribosome footprint density) per transcript and the 
location of ribosomes on a transcript (Ingolia, Ghaemmaghami et al. 2009). Ribosome footprints 
are obtained by nuclease digestion of RNA that is not ribosome bound, which leaves ribosome 
protected RNA fragments (footprints). Ribosome footprints are then released from ribosomes 
and undergo size selection by gel electrophoresis followed by library generation for sequencing. 
Ribosome footprints are then sequenced to determine the ribosome footprint density which is 
used to calculate the translation efficiency (TE) per transcript. TE is obtained by taking the ratio 
of ribosome footprint density over the total mRNA per gene (Ingolia, Ghaemmaghami et al. 
2009, Hornstein, Torres et al. 2016).  
The mTOR pathway is involved in regulating protein synthesis and is also frequently 
dysregulated in cancer (Akhavan, Cloughesy et al. 2010). Alterations in mTOR signaling have 
been associated with alterations in translational regulation both in neurological disease and 
cancer (Hoeffer and Klann 2010, Showkat, Beigh et al. 2014). In this chapter I describe 
published work where we used the Ribotag and Camk2aCre mouse to obtain neuron specific 
ribosome bound transcripts from normal brains treated with the mTOR inhibitor AZD. When 
crossing Ribotag and Camk2aCre mice the resulting strain expresses the HA-tagged ribosomal 
protein (Rpl22) in Camk2a+ neurons (figure 4.1c). This model then allows for the 
immunoprecipitation of neuron specific HA-tagged ribosomes and their associated transcripts 
which we characterized by RNA sequencing and ribosome profiling (Hornstein, Torres et al. 
2016). I also describe how we identified translational alterations using ribosome profiling in 
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homogenate tissue from our Camk2a-Ribotag mouse glioma model. We discovered that these 
translational alterations include the upregulation of specific DNA methylation and demethylation 
genes suggesting that epigenetic modifications in glioma may be regulated at the level of 
translation. 
This chapter described the use of ribosome profiling to identify translational alterations in 
our Camk2a-Ribotag mouse glioma model. We have published a manuscript describing the use 
of ribosome profiling in normal brain tissue of Camk2a-Ribotag mice and the ability of ribosome 
profiling to detect a pharmacological perturbation (mTOR inhibition with AZD). We used 
ribosome profiling to identify translation efficiency alterations in Camk2a-Ribotag glioma brain 
tissue. From these experiments we identified an upregulation in the translation efficiency of 
genes associated with DNA methylation and demethylation which suggest that specific genes 
associated with epigenetics are regulated at the level of translation.  
4.2 Results 
Ribosome profiling in normal mouse brain suggests cell type specific translational regulation 
We performed ribosome profiling and RNA sequencing in the right frontal lobe of 
normal mouse brain. Ribosome profiling provided ribosome density and RNA sequencing 
provided the total mRNA abundance. Using this information we calculated the translation 
efficiency (TE) by dividing ribosome density by the total mRNA abundance. We observed a 
broad distribution of TEs suggesting that there is a high degree of translational regulation in 
normal brain (figure 4.1a). In collaboration with the Sims lab, our lab previously showed that 
glioma cells have a different TE compared to other cells in the brain tumor microenvironment 
which suggested that there is cell type specific regulation of translation (Gonzalez, Sims et al. 
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2014). To assess if there is cell type specific translational regulation, we used gene expression 
profiles from a previous study (Zhang, Chen et al. 2014) to identify cell type specific genes. To 
perform this analysis we calculated the TEs for cell type specific genes and sorted them from low 
to high TE, conducted GSEA analysis and obtained an enrichment score for each gene (figure 
4.1b). We performed this analysis for neuron, astrocyte, OPC, new oligodendrocyte, myelinating 
oligodendrocyte, microglia, and endothelial cell type specific genes. These data show that the 
most neuron specific genes have high and low TEs suggesting that there is a high degree of 
translational regulation. The most microglial specific genes show low levels of TE which is 
likely due to the fact that we are sampling healthy brain and thus microglia are not activated . 
Oligodendrocytes showed a diverse pattern of translation during oligodendrocyte development, 
OPC specific genes had a high TE whereas myelinating oligodendrocyte specific genes had a 
low TE. Diverse patterns of TE in cell type specific genes suggested that there is a high degree of 
translational regulation in normal brain (figure 4.1b). 
The Camk2a-Ribotag mouse allows for the enrichment of neuron specific transcripts 
The Camk2a-Ribotag mouse allowed us to isolate neuron specific ribosome bound 
mRNAs (figure 4.1c). We verified the expression of HA-tagged neurons by immunofluorescent 
staining in normal brain tissue (figure 4.1d). We homogenized brain tissue to obtain a total 
homogenate lysate, from this lysate we isolated neuron specific ribosome bound mRNAs by 
immunoprecipitating HA-tagged ribosomes with an HA-antibody. The total homogenate contains 
ribosome and non-ribosome bound transcripts while the immunoprecipitated (IP) fraction 
contains HA-tagged ribosomes. Then we isolated ribosome bound transcripts for RNA 
sequencing. To analyze this data we took the ratio of normalized counts from the IP over the 
homogenate to obtain an enrichment score (ES) for cell type specific genes (figure 4.1e). Our 
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data show high enrichment for excitatory neuron specific genes and depletion of genes specific 
to other cell types (inhibitory neurons, OPCs, oligodendrocytes, astrocytes) supporting our 
immunofluorescence results that HA expression is restricted to neurons in normal brain tissue.  
Ribosome profiling detects inhibition of mTOR with AZD in normal Camk2a-Ribotag mouse 
brain  
mTOR signaling is central in integrating and processing signals to maintain cell 
homeostasis which is thought to occur via translation through downstream effectors S6K1 and 
4EBP1. mTOR activation phosphorylates S6K1 which phosphorylates ribosomal protein S6 (S6) 
and activates translation. Phosphorylated S6 (pS6) induces the translation of mRNAs with a 5’ 
terminal oligopyrimidine motif (TOP) which includes genes for components of the translational 
machinery such as ribosomal proteins and elongation factors (Meyuhas 2000, Moschetta, Reale 
et al. 2014). To identify the effects of mTOR inhibition we treated normal mice with the ATP-
competitive mTOR inhibitor AZD8055 (AZD). We delivered AZD (20 mg/kg) by oral gavage 
and collected the right frontal lobe brain tissue one hour after administration. We used a short 
treatment so as to minimize the effects of de novo protein synthesis. We determined that pS6 
expression decreased in AZD treated brains as demonstrated by immunostaining and western 
blot (figure 4.2a,d), specifically in HA-tagged cortical neurons (figure 4.2a).  
To assess the effects of mTOR inhibition on the TE in normal brain we performed 
differential gene expression analysis of the TE in AZD treated vs vehicle treated using RiboDiff. 
These results showed a significant downregulation in the TE of TOP motif containing genes after 
1 hour AZD treatment in normal brain (figure 4.2b). We also showed that the decrease in TOP 
gene expression was undetectable by RNA sequencing alone which supports previous findings 
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that mRNA levels alone are not concordant with protein expression (Maier, Güell et al. 2009). 
We show that the alterations in TE were statistically significant, 37 genes were differentially 
translated, 25 of these were known TOP containing motif genes and the remaining 11 were 
ribosomal proteins (figure 4.2c). These data show that translational control of gene expression 
precedes transcriptional control of gene expression in response to mTOR inhibition with AZD. 
This is in agreement with the fact that stress or pharmacological interventions induce detectable 
changes in translation prior to transcription (Hsieh, Liu et al. 2012, Thoreen, Chantranupong et 
al. 2012). 
Ribosome profiling reveals an upregulation of DNA methylation and demethylation genes in 
homogenate Camk2a-Ribotag mouse glioma brain  
We performed ribosome profiling on homogenate lysate from Ribotag-Camk2a tumor 
brains to identify translational alterations. We decided to use ribosome profiling to identify 
translational alterations in addition to the translational alterations we determined by TRAP 
methods used in chapter 2 and 3 because ribosome profiling would provide additional 
information about the ribosome density and TE per mRNA. To assess differential gene 
expression based on TE in tumor homogenate vs normal brain homogenate we used the RiboDiff 
algorithm (Zhong, Karaletsos et al. 2015). From this analysis we identified 104 differentially 
translated genes (table 2, p<0.05). We used Panther to identify the gene ontologies (GO) 
associated with these 104 genes, for biological processes GOs we identified the DNA 
methylation or demethylation GO. This GO included Ezh2, Dnmt3a, and Tet1-3 (figure 4.4a-b) 
as the genes from our data that were enriched in this GO. Similarly, using these 104 genes for 
molecular function GOs we identified the methylcytosine dioxygenase activity GO, which 
included Tet1, Tet2, Tet3 genes (figure 3.4a). Ezh2, Dnmt3a, and Tet1-3 were translationally 
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upregulated (log2foldchange>0) in tumor homogenate tumor relative to normal brain 
homogenate (table 2). These results show that Ezh2, Dnmt3a, and Tet1-3 are translationally 
regulated in our glioma model and suggest that a similar mechanism might underlie their 
expression in human glioma.  
We attempted to perform ribosome profiling from IP in tumor brains, however we 
obtained low yield ribosome footprints. We generated sequencing libraries from IP in tumor 
brains however we did not sequence them since it was advised by our collaborators that the 
quality of our sequencing data would be poor because of the low yield in ribosome footprints. 
We determined that there ribosome footprints had low yield during the size selection by gel 
electrophoresis step of library generation. 
4.3 Discussion 
In this chapter I described how we used ribosome profiling to identify translational 
alterations in mouse brain tissue. I described how we used ribosome profiling in normal brain 
from Camk2a-Ribotag mice to test the effects of mTOR inhibition with AZD. Ribosome 
profiling revealed that mTOR inhibition with AZD induced a translational downregulation of 
TOP motif genes which are canonical mTOR targets. Lastly, we identified that diffusely 
infiltrating glioma cells induced a translational upregulation of DNA methylation and 
demethylation genes in our Camk2a-Ribotag mouse glioma model. 
We showed that administration of the mTOR inhibitor AZD to normal Camk2a-Ribotag 
mice, reduced pS6 levels in cortical neurons and translationally downregulated TOP-motif 
containing genes (Hornstein, Torres et al. 2016). Treatment with AZD lasted for one hour, 
demonstrating that translational downregulation of TOP-motif genes is an early event after 
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mTOR inhibition with AZD. From the genes that were translationally downregulated after one 
hour AZD treatment, we did not identify known cell type specific genes. This could be due to the 
short duration of mTOR inhibition, suggesting that translational regulation of cell type specific 
genes might require longer mTOR inhibition to be detectable.  
The upregulation of DNA methylation and demethylation genes in our mouse glioma 
model support previous studies that show upregulation of some of these genes in glioma 
(Etcheverry, Aubry et al. 2010). DNA methylation is associated with transcriptional repression 
of tumor suppressor genes in cancer, thereby enabling tumor growth (Maleszewska and 
Kaminska 2013). Dnmt3a is a methyltransferase that establishes new methylation patterns in 
unmethylated DNA regions during development. Ezh2 is a histone methyltransferase that 
promotes transcriptional silencing, particularly of genes associated with lineage specification 
suggesting that Ezh2 promotes tumor growth by suppressing differentiation (Kim and Roberts 
2016). It has been shown that Dnmt3a and Ezh2 are upregulated in GBM which suggests that 
expression of these epigenetic markers may contribute to glioma growth (Etcheverry, Aubry et 
al. 2010).  Ezh2 was shown to have a higher translation rate in transformed glioma cells relative 
to normal brain in a different glioma mouse model (PDGFB-p53 retrovirally induced model) that 
is also used in our lab (Gonzalez, Sims et al. 2014). This suggests that Ezh2 may underlie tumor 
growth mechanisms that are common in both glioma models. 
Several studies have shown that Tet proteins are involved in the reversal of DNA 
methylation and that depletion of Tet genes are associated with enhanced tumor growth (Bian, Li 
et al. 2014, Rasmussen and Helin 2016). However, another study showed that there is an 
upregulation of Tet1 in proneural glioma cell lines compared to other glioma subtypes (Takai, 
Masuda et al. 2014). Our tumor model is considered a proneural glioma due to the genetic 
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alterations in PDGFRa and p53 . It is possible that studies that show downregulation of Tet 
isoforms grouped did not distinguish among glioma subtypes and as a result did not detect Tet1 
expression specifically in proneural glioma.   
We performed ribosome profiling on tumor homogenate, which includes all cells found 
in the tumor microenviroment thus we cannot determine the cell type specific contribution of 
Tet1 upregulation. We can infer that the upregulation in Tet1 is primarily a contributed to by 
glioma cells since glioma cells compose the majority of cells in tumor homogenate. However, it 
would be ideal to determine which cell type contributes to the upregulation of these epigenetic 
alterations by performing ribosome profiling on cell type specific ribosome bound transcripts. It 
is possible that the upregulation of Tet1 expression is a result of alterations in synaptic plasticity. 
Overexpression of Tet1 induced an upregulation of synaptic plasticity genes (Santiago, Antunes 
et al. 2014) which suggests that the upregulation of Tet1 may be a compensatory mechanism that 
tries to restore the expression of genes involved in synaptic plasticity in our glioma model.  
The results described in this chapter show how ribosome profiling can be used to identify 
translational alterations in response to mTOR inhibition with AZD in mouse brain. We applied 
ribosome profiling to our Camk2a-Ribotag mouse glioma model and identified a translational 
upregulation in the expression of epigenetic genes which suggests a mechanism for the 
expression of these genes. These findings provide the framework for future studies that will 























Figure 4.1: Unique patterns in the translation efficiency of cell type-specific genes in 
normal Camk2a-Ribotag mouse brain. A, The broad range of translation efficiencies 
(TEs) across genes expressed in normal mouse brain based on ribosome profiling. B, TEs 
measured in two different normal mouse brains with ribosome profiling were combined 
with cell type-specific gene expression profiles to associate cell type-specific gene 
expression and TE. We used gene set enrichment analysis (GSEA) to associate gene sets 
assembled from genes with similar TEs with a ranked list of all genes ordered by cell type-
specificity for each cell type in the brain. The resulting heatmaps show the enrichment of 
genes with different TEs in cell type-specific genes for each cell type. B, The Ribotag 
mouse model shows how the Camk2a-Ribotag mouse was generated. This provides an 
orthogonal means of identifying neuron-specific genes that are actively translated. D, 
Fluorescence imaging shows that Rpl22-HA (from the Ribotag allele) expression is 
specific NeuN+ cells (a pan-neuronal marker). D, Heatmap of the Ribotag enrichment 
scores following immunoprecipitation of polysomes from Camk2a-Ribotag normal mouse 
brains demonstrates strong enrichment of genes specific to excitatory neurons and 


















Figure 4.2: mTOR controls TOP motif-containing genes in normal Camk2a-Ribotag 
mouse brain. A, Treatment for 1 hour with AZD-8055 was sufficient to drastically 
decrease levels of pS6 in normal mouse brains. HA-staining indicates the presence of HA-
tagged Camk2a+ neurons. B, Comparison of RNA and TE fold changes between AZD 
treated and untreated mice. TE exhibits larger amplitude changes than RNA levels in 
response to mTOR inhibition in the brain. The TE of TOP motif-containing genes are 
greatly reduced. C, We used RiboDiff to identify genes with significant differential 
translation efficiency and DESeq2 to identify genes with significant differential RNA 
expression in treated versus untreated mice. The Venn diagram shows the overlap between 
genes with significant translational reduction after AZD treatment, ribosomal proteins, and 
TOP motif-containing genes. D, western blot of pS6 and S6 expression from right frontal 



































gene P-value log2(Tumor /Normal) gene P-value log2(Tumor /Normal) gene P-value log2(Tumor /Normal)
Nup93 0.000E+00 1.350 Adamts10 2.712E-03 3.658 Leng8 1.755E-02 0.784
Agrn 0.000E+00 1.165 Ascc2 3.069E-03 0.934 Fbxo5 1.805E-02 3.161
Col5a1 5.290E-13 3.132 Ccnb2 3.776E-03 3.286 Cpsf4 1.969E-02 1.370
Ezh2 2.010E-10 2.637 Igsf9b 4.351E-03 1.861 0610030E20Rik2.252E-02 2.151
Flnb 1.160E-09 1.564 Hmgb1 4.703E-03 -1.407 Smarca1 2.348E-02 0.699
Srsf9 1.970E-09 1.982 Fbn2 4.828E-03 3.278 Dnahc2 2.399E-02 1.854
Prr22 1.460E-07 6.712 Darc 4.971E-03 6.186 Arhgap22 2.481E-02 1.725
Dnmt3a 1.710E-07 1.417 Brwd3 4.971E-03 1.159 Rbm4 2.489E-02 1.034
Pkd1 1.920E-07 1.516 Mmp16 4.971E-03 0.695 Akap13 2.748E-02 0.762
Clasrp 1.920E-07 1.519 Gas2 5.405E-03 1.590 Wdr90 2.748E-02 1.331
Ctnnal1 1.950E-06 1.714 Dennd1b 5.453E-03 1.343 Chd7 2.748E-02 1.296
Snrnp70 2.060E-06 0.828 Paxbp1 6.749E-03 0.914 Atg16l2 2.819E-02 1.385
Col20a1 8.140E-06 3.526 Mdn1 7.366E-03 0.810 Asun 2.886E-02 0.668
Tet2 3.350E-05 2.041 Rpl37 7.366E-03 1.506 Lrch3 3.219E-02 0.832
Arpc1a 3.810E-05 -1.109 Bub1b 7.662E-03 1.680 Ube2r2 3.219E-02 -0.496
Myo9b 6.930E-05 1.698 Obsl1 7.815E-03 0.919 Nvl 3.267E-02 0.827
Fam173a 6.930E-05 -1.199 Tet1 8.253E-03 1.855 Nbeal2 3.612E-02 1.601
Pcdhb3 7.790E-05 -2.925 Cdyl 8.949E-03 1.258 Trpm4 3.627E-02 1.404
Pstpip2 1.480E-04 1.787 Pask 8.949E-03 2.195 Gatm 3.769E-02 0.556
Col11a1 2.290E-04 2.647 Pdia5 8.949E-03 1.938 Ttc28 4.140E-02 0.850
Tacc3 3.040E-04 1.932 Gm17296 8.949E-03 1.270 Ankrd28 4.140E-02 -0.725
Wsb1 3.810E-04 1.155 Ppp4r1 8.949E-03 0.939 Usp40 4.435E-02 1.035
Dcx 3.810E-04 1.895 Col6a1 8.949E-03 1.047 Pagr1a 4.517E-02 0.746
Flna 4.020E-04 1.013 Dynlt1b 9.079E-03 3.526 Casp2 4.580E-02 0.947
Rgl2 4.470E-04 1.498 Mroh8 9.398E-03 2.933 Ltbp4 4.580E-02 0.596
Apex2 4.760E-04 1.514 Pcdh15 9.492E-03 0.790 Klhdc4 4.580E-02 1.014
Xylt1 1.130E-03 0.838 Pcdhgb8 1.014E-02 2.172 Rpap1 4.796E-02 0.628
Tet3 1.130E-03 1.718 Ugdh 1.108E-02 1.240
Dot1l 1.130E-03 1.623 Gpr183 1.112E-02 -2.702
Pcbp4 1.130E-03 0.732 Tmem181a 1.421E-02 1.161
Sbf2 1.130E-03 0.906 Cryab 1.447E-02 -0.993
Kif21b 1.201E-03 0.873 Nup160 1.447E-02 0.796
Sec24a 2.322E-03 1.139 Tnpo1 1.453E-02 0.812
Mpzl1 2.404E-03 1.666 Smpdl3a 1.560E-02 -0.797
Lepre1 2.411E-03 1.668 Dusp11 1.560E-02 1.133
Dnahc8 2.411E-03 2.233 Nup188 1.587E-02 0.882
Spag5 2.484E-03 1.329 Cep112 1.632E-02 1.827
Stk38 2.712E-03 1.220 Megf6 1.632E-02 2.224
Table 2: Differentially translated genes determined by ribosome profiling (p<0.05) in 




















Figure 4.4: Gene ontologies for differentially translated genes in homogenate glioma 
mouse brains. A, Gene ontologies of 104 significantly translated genes from total 
homogenate of 3 tumor brains for GO biological process and GO molecular function. B, 
table of genes found in the DNA methylation or demethylation GO with corresponding 
adjusted p-value and log2 (translation efficiency fold change) from RiboDiff analysis, Tet1-
3 are the 3 genes from our list found in the methylcytosine dioxygenase activity GO.    
A 




Conclusions and future directions 
 
Conclusions 
In this thesis we used the Camk2a-Ribotag mouse glioma model to identify translational 
alterations specifically in neurons found in the glioma infiltrated cortex. In chapter 2 we use 
TRAP methods to show that there is a downregulation in the translation of synaptic genes in 
glioma tissue which is likely correlated with the decrease in dendritic spine density we 
discovered using diolistic imaging. Using TRAP we also show that there is an increase in the 
translation of actin binding genes associated with dendritic morphology and plasticity which 
overall suggest that there is a compensatory mechanism taking place in our glioma model. In 
chapter 3 we also use TRAP methods to show that mTOR inhibition with AZD reversed several 
of the neuron specific translational alterations induced by the tumor. In chapter 4 we used 
ribosome profiling to identify translational alterations after mTOR inhibition with AZD in 
normal brain and we show how we applied ribosome profiling to identify the translational 
upregulation of genes associated with DNA methylation and demethylation in our glioma model. 
Overall these findings show how our mouse glioma model can be used to identify cell type 





A new diffusely infiltrating glioma mouse model reveals neuronal alterations in the brain tumor 
microenvironment 
The Camk2a-Ribotag mouse glioma model we developed proved to be an essential tool 
for identifying neuronal alterations in the brain tumor microenvironment. Our mouse model 
histologically depicts the intermingling of neurons and glioma cells, a characteristic that is 
prominent in human glioma (Wesseling, Kros et al. 2011). Using translational ribosome affinity 
purification (TRAP) (Doyle, Dougherty et al. 2008, Heiman, Kulicke et al. 2014) our system 
allowed us to identify translational alterations specifically in neurons that had not been identified 
before. Neuronal alterations in glioma have likely been undetected because of a few issues 1) 
there is a variably lower abundance of neurons within the tumor compared to normal brain 2) 
alterations in cellular composition obscure cell type specific alterations in bulk tumor 3) the 
harsh methods needed to dissociate brain tissue makes it difficult to isolate neurons (Poulin, 
Tasic et al. 2016). Our Camk2a-Ribotag mouse glioma model overcomes these issues by 
allowing us to tag ribosomes and selectively isolate ribosome bound neuronal transcripts from 
glioma infiltrated cortex. Using TRAP, we discovered that there is a downregulation in the 
translation of synaptic genes and an increase in the translation of dendritic spine genes in our 
glioma model. We also show that there is increased expression of drebrin, an actin binding 
protein in dendritic spines, in the synaptosomal fraction of tumor brains. We also demonstrate 
that dendritic spine density is decreased from Camk2a+ neurons. Together, these data suggest 
that there are alterations in the synaptic component of glioma brains, and that these alterations 




The effects of mTOR inhibition with AZD in the Camk2a-Ribotag mouse glioma model 
In our studies we detected an upregulation of mTOR activity in mouse glioma tumor 
tissue and showed that inhibition of mTOR with AZD decreased mTOR activity particularly in 
neurons. This led us to conclude that AZD effectively targets mTOR in brain tumor tissue. Using 
TRAP methods we demonstrate that many of the neuron specific signatures, including genes 
associated with synapses and actin binding genes, were reversed after a 6 hour treatment with 
AZD. This shows that mTOR can regulate the translation of many neuron specific genes 
including dendritic spine and synaptic genes in our glioma model as was determined by TRAP. 
The observation that AZD can reverse the alterations in synaptic and dendritic spine genes 
suggests that mTOR signaling is a potential mechanism underlying neuronal alterations in 
glioma infiltrated cortex.  
Ribosome profiling reveals translational alterations in the Camk2a-Ribotag mouse glioma model 
Ribosome profiling provides a measure of translation by measuring the number of 
ribosomes per transcript and the location of ribosomes in each transcript (Ingolia, 
Ghaemmaghami et al. 2009, Ingolia 2016). This method provides a quantitative measure of 
translation, which is not provided by TRAP, and one that allows for determining how efficiently 
a gene is translated (Kapeli and Yeo 2012). Using ribosome profiling we showed that cell type 
specific genes have varying translation efficiencies which suggests that they are under tight  
translational control in normal brain (Hornstein, Torres et al. 2016). We also show that mTOR 
inhibition with AZD resulted in a downregulation of canonical mTOR targets (TOP genes) in 
normal brain (Hornstein, Torres et al. 2016). These findings provided the framework for the 
ribosome profiling experiments we performed in glioma brain tissue. Using ribosome profiling 
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we identified alterations in the translation of genes associated with DNA methylation and 
demethylation in homogenate glioma brain tissue. This data provides evidence for the 
translational regulation of specific genes associated with epigenetic alterations.  
Future directions 
We identified a downregulation in the translation of several synaptic mRNAs specifically 
in neurons from glioma infiltrated cortex. Diolistic imaging also revealed that there were fewer 
dendritic spines in neurons from glioma infiltrated cortex, these findings suggest that there are 
fewer synapses or that the existing synapses are not functional within glioma tissue. To 
determine if synaptic mRNAs are translated into protein future studies could assess the 
expression of these synaptic transcripts at the protein level either by western blot analysis of the 
synaptosomal fraction and immunofluorescence analysis of glioma infiltrated cortex. Dendritic 
spines are dynamic structures that can alter their properties in response to synaptic stimuli 
(Hlushchenko, Koskinen et al. 2016). It would also be important to assess dendritic spine 
morphology, since different dendritic spine morphologies can indicate synaptic maturity which 
could help us understand if they are functional synapses (Lai and Ip 2013, Maiti, Manna et al. 
2015).  
The actin binding genes we identified as upregulated in neurons within glioma infiltrated 
brain tissue are also associated with genes enriched in neuronal RNA granules (El Fatimy, 
Davidovic et al. 2016). RNA granules carry specific mRNAs to be locally translated in 
subcellular neuronal compartments such as dendritic spines. Our findings suggest that the 
translation of locally regulated mRNAs is altered in neurons from glioma infiltrated cortex. One 
way to determine the translation efficiency is to perform ribosome profiling. All of our neuron 
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specific data has been obtained using TRAP methods in order to identify neuron specific 
ribosome bound transcripts, however this approach can only tell us whether a transcript has a 
ribosome on it, it does not distinguish transcripts that have one or more ribosomes bound. 
Ribosome profiling is able to tell us ribosome density in addition to providing data about the 
location of ribosomes on a transcript. Mapping the location and density of ribosomes on 
transcripts can provide mechanistic insights into the regulation of translation, for example 
increased levels of ribosome occupancy at specific sites provide evidence for ribosome pausing. 
Future experiments could include performing ribosome profiling on neuron specific ribosome 
bound transcripts to provide additional insight into how efficiently these transcripts are being 
translated. 
Our findings showed that mTOR inhibition reversed many of the alterations determined 
by TRAP methods, future experiments could characterize the functional consequences of mTOR 
inhibition on neuron specific alterations. This could include assessing protein levels of dendritic 
spine genes and synaptic genes after mTOR inhibition by western blot analysis of the 
synaptosomal fraction and by immunofluorescence analysis of glioma infiltrated cortex. 
Analyzing the effects of mTOR inhibition on dendritic spine density using diolistic imaging 
could also provide further evidence of the consequences of mTOR inhibition on dendritic spine 
dynamics within the glioma infiltrated cortex. Additionally, it would be important to characterize 
how dendritic spine morphology is affected by mTOR inhibition to better assess synaptic 
maturity. Ultimately it would be ideal to characterize the functional consequences of mTOR 
inhibition using our glioma model by measuring synaptic strength or performing 
electrophysiological measurements of neuronal activity. It will also be important to assess the 
effects of mTOR inhibition on the neurological symptoms observed in our mouse glioma model, 
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including seizures using video EEG or cognitive impairments using behavioral tests. These 
experiments could provide data regarding the effects of mTOR inhibition in a mouse model that 
resembles the histological and behavioral characteristics in low grade glioma, and suggest the 
use of mTOR inhibitors to target neurological dysfunction in low grade glioma. 
Ribosome profiling allowed us to determine translational alterations in DNA methylation 
and demethylation genes from bulk glioma tissue. It would be critical to further analyze these 
existing data to determine the location of ribosomes on these transcripts. This could inform us 
whether ribosomes are stalled or not and in what specific region of the transcript they are 
primarily found. Our results were obtained from homogenate glioma tissue, which contains 
tumor cells as well as many other cells found in the tumor microenvironment thus we cannot 
determine the cell type specificity. It would be useful to perform ribosome profiling on the 
neuron specific transcripts obtained from the IP fraction in Camk2a-Ribotag glioma brain tissue 
in order to identify the neuron specific translational alterations in glioma infiltrated cortex. 
The mouse glioma model we developed provides a useful tool for studying cell type 
specific alterations in glioma and could be used to identify alterations in other brain cell 
populations including astrocytes, microglia, endothelial cells and inhibitory neurons. This could 
provide a better understanding of how infiltrating glioma cells alter the brain tumor 
microenvironment. Overall, the work described in this thesis showed that there are alterations in 
dendritic spines and synaptic genes and that mTOR is a possible mechanism underlying these 
changes. Hopefully the findings obtained from this work will contribute to a better understanding 







6.1 Mouse models and tissue processing 
Camk2a-Ribotag mice 
Camk2a-Cre mice (JAX ID 005359) have the mouse calcium/calmodulin-dependent protein 
kinase II alpha (Camk2a) promoter driving Cre recombinase expression in the forebrain, 
specifically in principal excitatory neurons. Camk2a-Cre mice were crossed to Ribotag mice 
(JAX ID 011029) which contain a conditional knock-in allele where exon 4 of the ribosomal 
protein (Rpl22) is flanked by loxP sites, followed by an identical exon tagged with three repeated 
hemagglutinin epitope coding sequences (HA-tag). The resulting Camk2a-Ribotag cross 
expresses the HA-tagged Rpl22 protein in principal excitatory neurons. Camk2a-Cre 
heterozygotes were crossed to homozygous Ribotag mice and genotyped with primers for Cre 
(GCG GTC TGG CAG TAA AAA CTA TC (transgene), GTG AAA CAG CAT TGC TGT CAC 
TT (transgene), CTA GGC CAC AGA ATT GAA AGA TCT (internal positive control forward), 
GTA GGT GGA AAT TCT AGC ATC ATC C (internal positive control reverse)) and for 
Ribotag (GGG AGG CTT GCT GGA TAT G (forward), TTT CCA GAC ACA GGC TAA GTA 
CAC (reverse)). 
Previous reports have shown that recombination with the Camk2a promoter-driven cre begins 
during the third postnatal week and is completed by the fourth postnatal week (Tsien, Chen et al. 
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1996); therefore for experiments using normal brain, we chose to use mice that were 12-13 
weeks old. 
Stereotactic retroviral injection 
Transgenic C57BL/6 mice carrying loxP recognition sites at exon 7 of Trp53 were crossed with a 
reporter transgenic mouse containing a mCherry-luciferase fusion gene floxed by loxP sites. 
These mice were bred to homozygosity and gliomas were induced by stereotactic injection of a 
retrovirus expressing PDGFA and Cre recombinase into the subcortical white matter of the right 
frontal lobe in P4 neonates. PDGFA-IRES-Cre was tittered to 10
6
 in Ribotag-Astrocytes. To 
target the subcortical white matter in neonates, we used coordinates of 1mm lateral, 1mm rostral 
and 1mm deep with bregma as the reference point. 1uL of retrovirus was injected using 
the coordinates described above and tumor growth was monitored by bioluminescent imaging as 
described previously (Lei, Sonabend et al. 2011). 
Glioma cell isolation from PDGFA induced tumor 
Tumor cells were isolated from a PDGFA retrovirally induced tumors (52 days post injection)for 
subsequent stereotactic injection in Camk2a-Ribotag adult mice.  The right frontal lobe of a 
PDGFA-p53 tumor bearing brain was dissected and washed in PBS. Tissue was minced and 
enzymatically dissociated with TrypLE at 37°C in a shaking water bath for 5 minutes. Tissue 
was triturated by passing through a 18G and 21G needle, filtered through a 70um mesh filter and 
neutralized with 50% FBS. Cells were collected by centrifugation and resuspended in cell culture 
media. Media was composed of DMEM, 10 ng/mL PDGF-AA (Peprotech), 10 
ng/mL bFGF (Peprotech), N2 supplement (Gibco), antibiotic/antimycotic, 0.5% FBS. Cells were 
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cultured and passaged in poly-l-lysine coated plates. As a result of the breeding cross, isolated 
cells express mCherry reporter which was visualized by fluorescent microscopy.   
Glioma cell injection into Camk2a-Ribotag mice 
Isolated glioma cells were stereotactically injected in adult (10-12 weeks old) Camk2a-Ribotag 
mice.  50,000 cells were resuspended in 2uL OptiMEM and were stereotactically injected to the 
subcortical white matter in the right frontal lobe of adult mice. To target the subcortical white 
matter in adults, we used coordinates of 2mm lateral, 2mm rostral and 2mm deep with bregma as 
the reference point. Tumor progression was monitored by bioluminescent imaging as previously 
described (Lei, Sonabend et al. 2011).   
Camk2a-Ribotag tumor bearing mice were sacrificed 5 weeks post injection (15-17 weeks old) 
for all experiments described. We chose this time period because starting at 4 weeks post-
injection mice begin to show signs of tumor morbidity. Mice were sacrificed by cervical 
dislocation and their brain was dissected and fixed in PFA for immunostaining and snap frozen 
in liquid nitrogen for RNA extraction and western blotting. 
Given the fact that I am using glioma cells derived from a retroviral induced glioma model to 
inject into the Camk2a-Ribotag mice I explored the differences among these two models. I 
compared the retrovirally induced model to the cell induced model using differential gene 
expression (DESeq) calculated for each tumor model. I determined that the many of the genes 
(83%) differentially expressed in the homogenate of the retrovirally induced model are also 
differentially expressed in the cell induced model suggesting that both models are similar  I 
assessed the GO of the similar genes and identified GOs that are associated with tumor cells 
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which suggests that both retroviral and cell induced models share similar genes that drive tumor 
growth.  
Luciferase imaging 
Bioluminescent imaging began 14 days post-injection in Camk2a-Ribotag mice, mice were 
imaged every week after that until they displayed signs of tumor morbidity. Mice were 
anesthetized with ketamine (100mg/kg) and given 100ul of luciferin substrate by IP injection. 
Bioluminescent imaging was performed 10 minutes after luciferin injection in the IVIS Spectrum 
Bioluminescence and Fluorescence Optical Imaging System at the Irving Cancer Research 
Center in Columbia University. 
Tissue processing and immunostaining 
Brains were collected for staining 5 weeks post injection (wpi) in adult Camk2a-Ribotag mice. 
At 5wpi brains were fixed in 4%PFA for 48h. For fluorescent staining, brains were cryoprotected 
in 10-30% sucrose for 2 days and embedded in OCT. Cryosections (12um) were fixed in 4%PFA 
for 15 minutes at room temperature, permeabilized with 0.5% Triton for 10 minutes, blocked 
with 5% goat serum for 1 hour and incubated with primary antibodies overnight at 4°C. Next 
day, sections were incubated with AlexaFluor conjugated secondary antibodies for 1 hour at 
room temperature and counter-stained with DAPI.  
For peroxidase staining, brains were embedded in paraffin, sections (5um) were immersed 
in xylene then rehydrated by incubation in 100%, 95%, and 75% ethanol. Antigen retrieval was 
performed in 10mM citrate buffer (pH 6.0) in a pressure cooker for 10 minutes. Slides were 
immersed in 3% hydrogen peroxide for 10 minutes to block endogenous peroxidases. Sections 
were blocked with 5% goat serum for 1 hour at room temperature and primary antibody 
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incubation was left overnight at 4°C. Next day, sections were incubated with biotin conjugated 
secondary antibodies for 1 hour at room temperature. ABC mixture was added to sections for 30 
minutes, followed by incubation with DAB chromogen until staining was observed. Sections 
were washed in water and counterstained with hematoxylin, dehydrated with 75%, 95% and 
100% ethanol and mounted with Permount. Sections were visualized with either a fluorescent or 
a light microscope and processed with Image J software.   
Tissue processing for RNA extraction 
Snap frozen tissue samples (5 mg) were homogenized at 4 °C with a Dounce homogenizer in 
1 mL of polysome lysis buffer (20 mM Tris-HCl pH 7.5, 250 mM NaCl, 15 mM MgCl2,1 mM 
DTT, 0.5 % Triton X-100, 0.024 U/ml TurboDNase, 0.48 U/mL RNasin, and 0.1 mg/ml 
cycloheximide). Homogenates were centrifuged for 10 minutes at 4 °C, 14,000 × g. The 
supernatant was removed and used for the isolation of ribosome footprints and total RNA. 
SUPERase-In (0.24U/mL) was added to the lysate used for total RNA to prevent RNA 
degradation. 
Drug delivery 
AZD-8055 (Selleckchem) was dissolved in Captisol and diluted to a final Captisol concentration 
of 30 % (w/v). A single dose of AZD-8055 was administered by oral gavage (20mg/kg) and 
delivered to normal Camk2a-Ribotag adult mice (12-13 weeks old). Vehicle consisted of 30 % 
captisol and was also delivered by oral gavage. Normal Camk2a-Ribotag mice were sacrificed 
1 hour after AZD-8055 or vehicle administration; two mice were used per condition. Cervical 
dislocation was performed and the right frontal lobe of the brain was collected and snap-frozen 
in liquid nitrogen prior to polysome extraction. The remaining brain lobes were fixed in 4 % 
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paraformaldehyde for 48 h and embedded in paraffin for histological analysis. The same protocol 
was followed for AZD time course experiments, except that mice were sacrificed between 1-24 
hours after AZD delivery and there were 2 doses of AZD delivered (20mg/kg or 100 mg/kg). For 
one mouse, AZD was delivered twice, the second dose was 1 hour before sacrificing for western 
blot analysis (25 hours AZD). 
AZD was delivered (100 mg/kg) by oral gavage to tumor bearing Camk2a-Ribotag mice (5 
weeks post glioma cell injection). Mice were sacrificed 6 hours after a single dose of AZD by 
cervical dislocation (treatment length determined based on previous experiments). Brains were 
dissected and the right frontal lobe was snap frozen in liquid nitrogen for RNA extraction, the 
rest of the brain was fixed in 4% PFA for immunohistochemistry. 
Western blotting 
Tissue was collected 1-25 hours after vehicle or AZD-8055 administration (20 mg/kg or 
100 mg/kg AZD-8055). The right frontal brain lobe was lysed from male mice that were 
12-15 weeks old. Tissue was lysed in 1 mL cell extraction buffer (Invitrogen 
#FNN10011) supplemented with protease (Sigma #P7626) and phosphatase inhibitors 
(Sigma#P5726, #P0044) with a Dounce homogenizer. Lysate was centrifuged and the 
supernatant was collected for total protein quantification. Total protein (30 μg) was 
loaded to a NuPAGE 4-12 % Bis-Tris gel and subject to gel electrophoresis according to 
the manufacturer’s instructions (Invitrogen #NP0321BOX). Bands were detected by 
fluorescent imaging using the Typhoon imaging system. Licor and HRP secondary 




The following primary antibodies were used for immunofluorescence and western blotting: 
mouse monoclonal anti-HA.11 ascites (1:500, Biolegend #901515), rabbit anti-pS6 S240/244 
(1:500, Cell Signaling #2215), rabbit anti-NeuN (1:500, Cell Signaling #12943), rabbit anti-pS6 
S235/236 (1:1000, Cell Signaling #2211), rabbit anti-S6 (1:1000, Cell Signaling #2217), rabbit 
anti-β-actin (1:1000, Cell Signaling #4970S). The following secondary antibodies were used for 
immunofluorescence and western blotting: goat anti-rabbit Alexa 488 (1:1000, Invitrogen 
#A11008) and goat anti-mouse Alexa 568 (1:1000, Invitrogen #A11031). 
Antibodies used for immuhistochemistry staining include rabbit anti-Olig2 (1:100, Millipore 
AB9610), mouse anti-HA (1:500, Biolegend #901515), mouse anti-NeuN (1:100, Millipore 
MAB 377), rabbit anti-Ki67 (1:500, Cell signaling 9129). The mouse anti-HA antibody was used 
for normal brain immunoprecipitations, and the rabbit polyclonal anti-HA (Abcam 9110) was 
used for tumor brain and treated tumor brain immunoprecipitations, we discovered that the rabbit 
antibody gave better RNA quality and yield.  
6.2 Molecular biology for generating sequencing libraries 
Immunoprecipitation 
100 uL of lysate was used as input (total homogenate RNA) from which RNA was extracted 
using the RNeasy Mini kit (Qiagen). The remaining lysate was used for indirect 
immunoprecipitation (IP) of polysomes, we coupled 15uL of rabbit polyclonal anti-HA (abcam) 
to lysate with rotation at 4C for 4 hours. We used 150uL of protein G Dynabeads (30mg/mL, 
Life Technologies) and washed them with 600 uL polysome buffer. The conjugated lysate was 
then added to protein G-coated dynabeads and incubated with rotation at 4C overnight. Beads 
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were then washed with polysome buffer. RNA was extracted using the RNeasy Mini Kit and 
RNA integrity was assessed by Bioanalyzer (Agilent).  
RNA sequencing libraries 
RNA samples from Camk2a-Ribotag normal brain tissue were provided to the Columbia 
Sulzberger Genome Center for poly(A)-selection and RNA-Seq using the Illumina TruSeq kit. A 
total of four RNASeq libraries were generated for AZD-treated and vehicle normal mice. 
RNASeq libraries were generated from matched samples used in ligation-free ribosome profiling 
experiments. Four additional libraries were sequenced from non-ribosome profiling matched 
samples; two total input samples and two matched IP samples. 
RNA samples from Camk2a-Ribotag tumor bearing tissue were depleted of ribosomal RNA 
using Ribo-Zero rRNA Removal Kit (MRZH11124) according to the manufacturer’s protocol 
prior to library generation. Libraries were generated using the NEBNext Ultra Directional RNA 
Library Prep Kit for Illumina from New England Biolabs (E7420S) according to the 
manufacturer’s protocol. Three RNASeq libraries were generated from total RNA from different 
three tumor brains. Three additional RNASeq libraries were generated from the polysome IP of 
the same three tumor brains. 
Ribosome profiling libraries 
Ribosome profiling libraries were generated from the same six total RNA samples described 
above, three tumor brains and three normal brains, using the SMARTer smRNA-Seq Kit for 
Illumina from Clontech laboratories (635029) as described previously (Hornstein, Torres et al. 
2016). Briefly, ribosome footprints were isolated with a sucrose gradient, size selected and 
dephosphorylated. Ribosome footprints were polyadenylated, reverse transcribed, depleted of 
97 
 
ribosomal RNA using complimentary oligos, amplified by PCR and validated with bioanalyzer 
prior to sequencing.    
6.3 Analysis of dendritic spine genes and dendritic spine density 
Synaptosome isolation 
The right frontal lobe from 5 tumor and 5 non-tumor bearing Camk2a-Ribotag mice was used for 
synaptosome isolation. I followed a synaptosome isolation protocol that has been previously 
described with a few modifications (Smalheiser and Lugli 2014). The tissue was flash frozen in 
liquid nitrogen and stored in liquid nitrogen until lysed. Tissue was lysed in 1mL 
homogenization buffer (50mM Hepes, 125mM NaCl, 100mM sucrose, 1:100 protease cocktail 
inhibitor) using a Dounce homogenizer on ice. 75uL of this lysate was saved for total 
homogenate, the rest was centrifuged at a low speed (1000g) for 10 minutes at 4 degrees, the 
pellet contained nuclear components and was saved. The supernatant was centrifuged (15000g) 
for 15 minutes at 4 degrees, the pellet contained crude synaptic membranes and was first washed 
then resuspended in 75uL cell extraction buffer (described above). The supernatant contained 
cytoplasmic components and was saved. The total, cytoplasmic and synaptic fractions were used 
for protein quantification using the BioRad DC Protein assay then used for western blot analysis 
as described above.  
Diolistic labelling of brain sections and image analysis 
DiI-coated tungsten particle preparation, delivery and tissue labeling were performed as 
described in (Staffend and Meisel 2011) with minor modifications. Mice were anaesthetized 
using a mixture of ketamine and xylaxine (100/10 mg/kg) and perfused with 10 mL PBS 
followed by 20 mL of a 2% PFA solution at a rate of 5 mL/min. Brains were removed, post-fixed 
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for 10 minutes in 2% PFA and transferred to PBS. 200 μm-thick coronal sections were acquired 
on a vibratome (Leica). Sections were labelled by delivery of DiI-coated tungsten beads using a 
Helios gene gun (Biorad) at 120 psi. DiI was allowed to diffuse for 24 hours at 4
o
C followed by 
post-fixation with 4% PFA for 1 hour at room temperature. 
For antibody staining of DiI-labelled tissue, sections were permeabilized for 15 minutes in 0.1% 
Triton-X 100 in PBS and blocked in 0.01% Triton-X 100, 10% normal goat serum in PBS for 30 
minutes at room temperature. Primary antibody (anti-HA; HA11 Covance) incubation was 
performed overnight at room temperature, followed by counterstain with secondary antibody and 
DAPI for 1 hour at room temperature. Sections were mounted on glass slides and imaged on an 
inverted Zeiss LSM 800 confocal microscope using a 63X/1.4 NA or a 40X/1.3 NA oil 
immersion objective. Images of whole labelled neurons were acquired at 1 μm steps. Z-stacks of 
dendritic spines were acquired at a frame size of 50.71×50.71μm (1024×1024 pixels) and a step 
size of 0.2 μm. Dendritic spine number was counted manually with the help 
of FIJI software (NIH).  
6.4 Bioinformatics analysis 
Mapping RNA sequencing libraries 
The RNA-Seq data were aligned to the mm10 genome and RefSeq transcriptome annotation 
using the STAR aligner (Dobin, Davis et al. 2013) and quantified using the featureCounts 
program in the subread package (Liao, Smyth et al. 2014).  
Enrichment score 
Enrichment scores were derived from three normal brain IP experiments and the corresponding 
homogenates. The enrichment score was determined for each gene by first normalizing counts in 
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the IP and homogenate by size factors generated from DESeq2. Following normalization, the 
enrichment scores were calculated by dividing normalized IP counts by normalized homogenate 
counts as previously described (Hornstein, Torres et al. 2016). This analysis was also performed 
for 3 tumor brain IP experiments and their corresponding homogenates and 3 AZD treated tumor 
brain IPs and their corresponding homogenate. For the experiments described in chapter 2 and 3 
we used an enrichment score cutoff of 1.5, genes with and ES>1.5 were considered enriched.  
Differential gene expression  
Differential expression analysis was accomplished using DESeq2 (Love, Huber et al. 2014). 
Differential gene expression analysis for RNA sequencing counts was performed using DESeq2 
for 3 tumor brains vs 3 normal brains and for 3 AZD treated tumor brains vs 3 untreated tumor 
brains. This analysis was performed for tumor vs normal brain homogenate, tumor IP vs normal 
brain IP, AZD treated tumor homogenate vs untreated tumor homogenate, AZD treated tumor IP 
vs untreated tumor IP. From these analysis, only genes with p<0.05 were considered 
differentially expressed genes. This analysis also revealed whether differentially expressed genes 
were upregulated (log2 fold change>0) or downregulated (log2 fold change<0).  
Gene ontology 
Gene ontology analysis was performed using the panther classification system (Thomas, 
Campbell et al. 2003). Gene ontology enrichment analysis was performed for molecular function 
and only the top 2-5 gene ontologies are shown in our figures. We also used DAVID gene 
ontology analysis for experiments described in chapter 3 (Huang, Sherman et al. 2008, Huang, 
Sherman et al. 2009). Gene ontology analysis for chapter 4 was performed as described 





To calculate translation efficiency and analyze differential translation efficiency we used the 
RiboDiff algorithm as described before (Zhong, Karaletsos et al. 2015, Hornstein, Torres et al. 
2016). This analysis was performed for differential translation efficiency between normal brain 
vs AZD treated normal brain and tumor homogenate vs normal brain homogenate.  
Gene set enrichment analysis (GSEA) 
GSEA was performed as described for the published experiments in chapter 4. The results were 
used to define which genes were most associated with specific cell types. GSEA was performed 
for normal brain and tumor brains using the list of neuron specific genes from a previous study 
(Zhang, Chen et al. 2014). GSEA was also performed for the homogenate and IP tumor data 
using the list of genes enriched in RNA granules from a previous study (El Fatimy, Davidovic et 
al. 2016). Gene set enrichment analysis was done using the GSEA Java program from the Broad 
Institute in “pre-ranked/classic” mode after removing all genes in the annotation that do not 
encode proteins (Subramanian, Tamayo et al. 2005). Genes were ranked either by their RiboTag 
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